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ABSTRACT
Chronic kidney disease (CKD) affects more than 30 million adults in the U.S. and
is strongly associated with cardiovascular events and mortality. Venous
thromboembolism (VTE) is the third leading vascular disease, affects up to 900,000
Americans each year and contributes to as many as 100,000 deaths annually. The
relationship of CKD and VTE has been described in patients receiving dialysis, kidney
transplants recipients and in nephrotic syndrome, however, data supporting the
association of VTE in mild to moderate CKD is conflicted. The overall goal of this
research was to study the association of CKD and VTE and to understand the
mechanisms of this association. To accomplish this goal we studied participants of the
Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study, a
nationally representative cohort of 30,239 blacks and whites in the U.S..
The first chapter provides a review of the state-of-the science on CKD and VTE
and potential mechanisms for this association. We focus on factor VIII as a potential
mediator of VTE risk in CKD by reviewing the biochemistry and epidemiology linking
factor VIII and CKD.
In Chapter 2, we use a cohort study design and a competing risk analysis to
determine the risk of VTE with albuminuria (ACR) and with various equations for
estimated glomerular filtration rate (eGFR). There was no association of ACR and VTE
and the risk of VTE was similar among eGFR equations. Compared to a normal eGFR
(>90 ml/min/1.73m2), eGFR < 45 ml/min/1.73m2 was associated with a two-fold risk of
VTE. The association of eGFR and unprovoked VTE was similar to the association with
provoked VTE. The population attributable fraction of CKD (eGFR<60 ml/min/1.73m2)
was modest at 5%.
In Chapter 3, we utilize a case-cohort study to determine if biomarkers of
inflammation (C-reactive protein) and procoagulation (Factor VIII and D-dimer)
attenuate the risk of VTE in CKD. These biomarkers were higher in lower kidney
function and were also strongly associated with VTE. Adjustment for factor VIII fully
attenuated the risk of VTE in CKD, thus factor VIII is a potential mediator of the
association of CKD and VTE. We assessed whether lifestyle factors and medications
mitigate the risk of VTE in those with and without CKD. Exercise frequency and use of
statins were associated with reduced risk of VTE in the presence and absence of CKD,
but normal BMI was associated with reduced VTE risk only in those without CKD.
We conclude that CKD is a risk factor for VTE, and findings shed light on the
mechanisms of this association. Interventions that might lower VTE risk in CKD patients
include exercise and statin therapy, but not weight loss. Factor VIII is a potential
mediator of VTE in CKD and deserves further study. We suggest several avenues for
future research to explore the relationship of Factor VIII and CKD.
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CHAPTER 1: VENOUS THROMBOEMBOLISM, FACTOR VIII AND CHRONIC
KIDNEY DISEASE

Katharine L. Cheung Larner College of Medicine, at the University of Vermont
Beth A. Bouchard, Larner College of Medicine, at the University of Vermont
Mary Cushman, Larner College of Medicine, at the University of Vermont
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1.1. Abstract
Chronic kidney disease (CKD) affects 30 million Americans and is associated
with approximately a two-fold increased risk of venous thromboembolism (VTE). There
is a graded increased risk of VTE across declining estimated glomerular filtration rate
(eGFR) and increasing albuminuria, and the risk varies by cause of CKD. Compared to
the general population, VTE in end-stage kidney disease (ESKD) is associated with
greater hospitalization and higher mortality. Mortality associated with PE in ESKD also
varies by cause of ESKD. Transplant patients with VTE are at a greater risk for death and
graft loss than transplant patients without VTE. The reasons for VTE in CKD are not well
understood but recent data suggest that Factor VIII (FVIII) is a mediator of VTE in CKD.
FVIII is an essential cofactor in the coagulation cascade and a strong risk marker for VTE
in general. It is inversely correlated with eGFR and prospective studies demonstrate that
FVIII activity predicts CKD and rapid eGFR decline. This review summarizes the
epidemiology of CKD with VTE, reviews the biochemistry and determinants of FVIII,
including von Willebrand factor and ABO blood group, outlines the epidemiology of
FVIII and CKD, and suggests future research directions.
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1.2. Introduction
Chronic kidney disease (CKD) affects 15% of the adult U.S. population and the
prevalence is increasing, in part due to the aging population.1 The two most common
causes of CKD are diabetes and hypertension.2 CKD can lead to important health
consequences including anemia, metabolic acidosis, bone disease, immune dysfunction
and lower quality of life.2 There is also an increased risk of death and cardiovascular
events including stroke, coronary disease, heart failure and peripheral arterial disease in
CKD.3 The heightened risk of vascular diseases in CKD is not limited to the arterial
circulation. Emerging evidence reveals an association between CKD and venous
thromboembolism (VTE).4-7
VTE consists of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is
the third leading vascular disease6,8-10 and costs the US healthcare system $7-10 billion
each year.11 VTE affects up to 900,000 Americans annually and contributes to 60100,000 deaths each year.12 Approximately 25% of people who have a PE experience
sudden death13 and for VTE the 28-day case fatality is 11%.14 Among those who
experience a DVT, up to one-half will go on to develop chronic venous insufficiency
and/or post thrombotic syndrome.13 Also, VTE recurs in one-third of people within ten
years.13 About half of VTE are provoked by surgery, trauma, cancer or immobilization
and half are unprovoked. Given that there is no identifiable provoking factor in half of all
VTE cases, research on novel risk factors and mechanisms of VTE is important. The risk
of VTE increases with lower kidney function,7 and VTE carries a higher risk of death in
CKD than the general population.15
3

FVIII is an acute phase reactant16 that is elevated in stress17, inflammation18 and
exertion.19 Elevated FVIII also represents a procoagulant state and endothelial injury. It is
elevated with increased age, BMI, total cholesterol and in diabetes.20 FVIII is a strong
and independent risk factor for VTE; in the Leiden Thrombophilia Study (LETS) FVIII 
150% was associated with a 5-fold increased risk of VTE compared to FVIII <100%,
after controlling for BMI, diabetes, smoking, ABO blood group and vWF.21 FVIII
remained a strong risk factor after controlling for fibrinogen, an acute phase reactant, and
C-reactive protein, an inflammatory marker that is often elevated in the acute phase.22
The reasons for VTE in CKD are not well understood. The classical
pathophysiological explanation for VTE, as attributed to Virchow, implicated the triad of
a hypercoagulable state, stasis of blood and vascular injury.23,24 Over the past few
decades a greater understanding of the pathophysiology of VTE has been described
including delineation of prothrombotic genetic factors (Factor V Leiden and prothrombin
gene mutation 20210A),25 procoagulant and inflammatory pathways26 and the influence
of obesity27,28 Of these risk factors, procoagulant and inflammatory pathways are
candidate mediators for VTE in CKD given the heightened procoagulant and
inflammatory state that accompanies CKD. As the increased risk of VTE in CKD has
been only recently reported, little research exists studying the mechanisms of this
association. The Multiple Environmental and Genetic Assessment of risk factors for
venous thrombosis (MEGA) study, a case-control study of patients with VTE and
controls, identified that the relationship between CKD and VTE could be explained by
von Willebrand factor and Factor VIII.29 In the Reasons for Geographic And Racial
4

Differences in Stroke (REGARDS) study, a case-cohort analysis showed that Factor VIII
completely accounted for the association between CKD and VTE.30 In this review we
provide an overview of the epidemiology of CKD and VTE. Given the importance of
Factor VIII in this relationship, we summarize the literature on CKD and FVIII, identify
potential pathogenic pathways involved, discuss limitations of current literature and
explore research gaps for future investigations.

Definitions of Chronic Kidney Disease
CKD is defined as a reduced glomerular filtration rate (GFR) or elevated
albuminuria that is present for a minimum of three months.31 Since glomerular filtration
rate is not easily measured in practice, estimated GFR (eGFR) is calculated based on
equations that include serum creatinine (and or cystatin C), age, sex and race. Less
commonly studies cited in this review defined CKD based on a threshold of serum
creatinine (or cystatin C). For the purposes of surveillance and in most epidemiological
studies, CKD is defined based on one measurement of eGFR or albuminuria.1
Albuminuria is measured using the urinary albumin-to-creatinine ratio (ACR) and is
categorized as <30 mg/g (normal to mildly increased), 30-<300 mg/g (moderately
increased) and  300 mg/g (severely increased). The kidney has many functions beyond
that of filtration including production of hormones such as erythropoietin and activated
vitamin D, regulation of volume status, tonicity and pH and metabolism and excretion of
drugs. A decline in eGFR is approximately paralleled by a decline in other kidney
functions and is the most commonly used clinical measure of kidney function.
5

1.3. Association of Chronic Kidney Disease with Venous Thromboembolism
Mild to moderate kidney disease and VTE
There is growing evidence for an association of kidney disease and VTE,
although some of the data are conflicting depending on how kidney disease was defined
(Table 1.1). The Tromso study, which recruited community-dwelling adults age 25-84
years old from 1994-95, found that higher serum cystatin C was associated with a 2.5fold increased risk of VTE over 12.5-year median follow-up.32 The Atherosclerosis Risk
in Communities (ARIC) Study studied 10,700 self-identified white and black participants
age 45-64 years and used cystatin C-based eGFR. As compared to eGFR 90
ml/min/1.73m2, the adjusted hazard ratios (HRs) for eGFR 60-89 and 15-59
ml/min/1.73m2 were 1.26 and 1.60.33 Conversely, creatinine-based eGFR was not
associated with VTE occurrence in the ARIC study. In the Longitudinal Investigation of
Thromboembolism (LITE) study, which combined participants from ARIC and the
Cardiovascular Health Study (CHS), creatinine-based eGFR <60 ml/min/1.73m2 was
associated with an increased risk of VTE in middle age and older Americans.6 Given the
prior conflicting reports, The Reasons for Geographic and Racial Differences in Stroke
(REGARDS) study compared the risk of VTE among 30,239 adults age 45 and older
across the US, using different eGFR equations, including the combined creatininecystatin C based eGFR. This study reported a two-fold increased risk of VTE in
participants with creatinine-cystatin C based eGFR <45 compared to eGFR>90
ml/min/1.73m2,7 and a similar risk for the other eGFR equations. In addition, a meta6

analysis of five cohort studies, including LITE and Tromso, confirmed an association of
eGFR and VTE.4 Other types of studies have reported a relationship between eGFR and
VTE. The MEGA study was a case-control study that examined risk factors for venous
thrombosis. This study recruited consecutive patients from 1999-2004, aged 18-70 years,
who experienced a first VTE, and a control group. This study found an increased risk of
VTE with eGFR < 60 ml/min/1.73m2, and this risk was augmented by additional genetic
or acquired risk factors such as Factor V Leiden or immobilization. Interestingly, there
was also a J-shaped relationship between eGFR and VTE, where very high eGFR was
also associated with an increased risk of VTE.34 A large nationwide case-cohort study in
Denmark of 128,096 patients with a hospital diagnosis of VTE demonstrated that kidney
disease was associated with an increased risk of VTE. The risk also varied by etiology of
kidney disease. The adjusted OR of VTE for hypertensive nephropathy was 1.41 (95% CI
1.22, 1.63) and for nephrotic syndrome was 2.89 (95% CI 2.26, 3.69).35 In summary,
compared to normal eGFR, the risk of VTE for CKD is approximately 1.26-2.89-fold
depending on the definition of eGFR and etiology of CKD.
Albuminuria has also been linked to a higher risk of VTE, even at mildly
increased levels. In the Prevention of Renal and Vascular End-stage Disease
(PREVEND) study, which was enriched for participants with albuminuria, as compared
to minimal albuminuria (ACR < 30 mg/g) the adjusted HR (95% CI) of VTE for ACR
>30 mg/g was 2.0 (1.34, 2.98).5 In contrast, there was no association of albuminuria and
VTE in the REGARDS general population study.7 In the aforementioned meta-analysis,
as compared to ACR 5 mg/g, the HR for VTE increased linearly across ACR: 1.34 for
7

ACR 30mg/g, 1.60 for ACR 300 mg/g and 1.92 for ACR > 1000mg/g. This is consistent
with the marked increased risk of VTE in nephrotic syndrome,36,37 which presents with
proteinuria >3.5 grams/day. The mechanisms promoting VTE in this disease state may be
different.

End-stage kidney disease and VTE
There is an increased risk of VTE in patients with end-stage kidney disease
(ESKD) although it is not clear if the risk is similar or greater than in CKD. In the
Nationwide Inpatient Sample from the U.S., the incidence of PE per 100,000 was 66 in
those with normal kidney function, 204 in CKD and 527 in ESKD.15 Using data from the
U.S. Renal Data System and National Hospital Discharge Survey, the age-adjusted PErelated hospitalization incidence rate ratio was 2.11 in dialysis patients compared to the
general population.38 Similarly, in a study of National Health Insurance claims, the
incidence rate for PE in Taiwanese dialysis patients versus age- and sex-matched controls
was 0.92 versus 0.33 per 1000 person-years, and the adjusted HR (95% CI) for PE was
2.0 (1.63, 2.50),39 which is similar to the increased risk in CKD. It is unknown whether
hemodialysis poses a greater risk for VTE than peritoneal dialysis.8,39 Importantly, PE in
dialysis patients is associated with a high mortality rate. In a study comparing European
dialysis patients to the general population, it was reported that the age and sex
standardized mortality rate (SMR) for PE was 12 times higher in dialysis versus the
general population. This exceeds the SMR for myocardial infarction or stroke, which was
11 and 8 times higher in dialysis patients versus the general population.40 The Nationwide
8

Inpatient Sample study reported in-hospital mortality associated with PE was 50% greater
for CKD and 90% greater for ESKD compared to patients with normal kidney function.15
The cause of ESKD is also related to the risk of mortality associated with PE in dialysis
patients, with diabetes posing a greater risk than polycystic kidney disease.40

Kidney transplantation and VTE
There is an increased risk of VTE in kidney transplant patients as well and this is
related to the time since transplantation.41 As compared to patients with eGFR>30
ml/min/1.73m2, those with eGFR<30 have a 2-fold increased risk of VTE 1.5-3 years
after transplantation.42 The immediate risk of symptomatic VTE within 90 days of
transplant was 0.9% in a retrospective study of 441 consecutive kidney transplants from
Argentina,43 similar to the risk associated with relatively low risk surgeries. A Korean
study reported a 4% incidence of VTE within 90 days by screening for VTE with duplex
ultrasound, however only one patient was symptomatic.44 An Italian study of 538 kidney
transplant patients reported that 9% developed VTE with a median follow-up time of 17
months, and 40% were symptomatic.41 A larger, retrospective study of healthcare data
from Ontario, Canada studied 4,343 kidney transplant patients compared to 17,372
matched controls from the general population. The incidence rate of VTE in kidney
transplants was 7-fold greater than the general population but varied based on time since
transplant. The incidence rate of VTE was greatest in the first three months posttransplant, and while it declined over time it remained higher than the matched cohort.
Similar to patients with ESKD, VTE in kidney transplant patients confers significant
9

morbidity and mortality. Those who experience a post-transplant VTE had a four-fold
higher risk of death and a two-fold increased risk of death-censored graft loss compared
to matched recipients without VTE.45 Since kidney transplant patients with VTE were
more likely to have coronary heart disease, diabetes, peripheral vascular disease and
recent cancer than patients without VTE, and given that the median time to death and
death-censored graft loss was 1.8 years and 1.4 years, respectively, it seems likely that
death and graft loss were related to underlying disease rather than the VTE itself.

1.4. Mechanisms of Venous Thromboembolism in Chronic Kidney Disease
There is a myriad of risk factors for VTE, including older age, obesity, prior VTE,
active cancer, immobilization, recent hospitalization, surgery, or trauma, and
thrombophilia. Studies documenting associations of biomarkers with VTE risk, reveal the
importance of inflammation and procoagulation in the development of VTE. For
instance, higher D-dimer,46 FVIII47 and C-reactive protein26 are independently associated
with VTE risk. Similar directional changes in these biomarkers are seen in CKD,48,49 and
could be mediators for VTE in people with CKD. As previously noted, two recent studies
implicated FVIII as a potential mediator in the relationship of CKD and VTE.29,30 In the
MEGA and REGARDS studies, FVIII attenuated 100% of the relationship of CKD and
VTE. In comparison, reduced anticoagulant levels such as protein C, protein S and
antithrombin did not explain VTE risk in CKD in the MEGA study, and inflammation
had a more minor role than FVIII in the REGARDS study.29,30 Other potential
mechanisms for VTE in CKD, such as greater platelet activation or decreased fibrinolytic
10

activity, have not been studied (Figure 1.1.). Given that FVIII appears to mediate the
association of CKD and VTE, further study of the relationship between FVIII and CKD
is warranted.
Conceptually, there are at least three potential ways in which FVIII and CKD may
be related. FVIII may represent a manifestation of kidney disease itself, it may promote
kidney disease progression and/or it may be elevated due to the consequences of CKD
(Figure 1.2.). To explore this further, the remainder of this review will focus on the
biochemistry of FVIII as this may be influenced by complications of CKD, the
determinants of FVIII and what is known about shared determinants with CKD, and the
epidemiology of FVIII and CKD.

1.5. Biochemistry of Factor VIII
Structure
The FVIII gene is located on the X chromosome and encodes a large precursor
protein of 2,351 amino acids.50 FVIII is predominantly synthesized in the hepatic
sinusoidal cells although the natural cell type that produces FVIII has not been identified
and there are no known natural established cell lines that express FVIII.51 It is also
believed to be synthesized by glomerular endothelial cells based on data locating FVIII
mRNA in the kidney.52-54 The organizational structure of FVIII consists of six domains:
A1-A2-B-A3-C1-C2.55 In the Golgi compartment, FVIII is cleaved at two sites in the B
domain to produce the heavy (A1-A2-B) and light (A3-C1-C2) chains. It is then secreted
as a heterodimer with a molecular weight of approximately 280 kDa. The three A
11

domains are involved in protein-protein interactions, the B domain is removed by
thrombin activation and the two C domains are involved in phospholipid binding. Both
chains of this heterodimer contribute to the interaction with lipoprotein receptor-related
protein (LRP-1), a cell surface endocytic receptor expressed on a variety of human tissues
including monocytes, fibroblasts and smooth muscle cells and is involved in FVIII
clearance.56 The mature factor has 2,332 amino acids and circulates in plasma at a
concentration of 0.7 nM.57 FVIII contains one calcium and two copper binding sites, and
ion binding interactions may be important for both the structure and function of FVIII.
FVIII is heavily glycosylated, which is also important for its structure and function.58

Regulation by vWF
After FVIII is secreted by exocytosis and once in the plasma, it is stabilized by
non-covalent association with von Willebrand factor (vWF). This increases the half-life
of vWF-bound FVIII to about 10 hours59 by preventing inactivation by activated protein
C, FIXa and FXa.60,61 Deficiency of vWF-FVIII binding, as in von Willebrand disease
type 2N, results in a secondary FVIII deficiency, due to more efficient clearance from the
circulation.

FVIII activation, inactivation and clearance
FVIII is activated by thrombin through proteolytic cleavage at three sites. This
results in polypeptides A1 (50 kDa), A2 (43 kDa) and A3-C1-C2 (73 kDa). When A3 is
cleaved, FVIII dissociates from vWF and a heterotrimeric FVIIIa forms. The A1 subunit
12

derived from the heavy chain exists in a stable association with the light chain-derived
A3-C1-C2, which is weakly associated with the A2 subunit.62 In the presence of
phospholipids and calcium, activated FVIII (FVIIIa) forms a membrane-bound complex
with FIXa called the FXase complex.63,64 This complex then acts to convert FX to FXa, a
process that is amplified 100,000-fold by the presence of FVIIIa.65,66 FXa and its cofactor FVa form the prothrombinase complex, which activates prothrombin to thrombin.
Thrombin in turn catalyzes the conversion of soluble fibrinogen into fibrin.
FVIII is inactivated by two mechanisms. First, the A2 subunit spontaneously
dissociates when FVIII is activated, with a half-life of 2 minutes. Second, FVIIIa
undergoes proteolysis by activated protein C at two sites.67 The mechanisms for FVIII
clearance are not yet well characterized but several potential mechanisms have been
reported.68 Free FVIII is removed from circulation primarily in the liver by binding to
LDL-receptors, heparan sulphate proteoglycans (HSPGs), asialoglycoprotein receptors
and megalin.69 LRP-1 mediates cellular uptake and degradation of free FVIII57,70 through
interaction with the C2 and A2 domains, and is generally inhibited when FVIII is bound
to vWF with few exceptions.69,71 In mouse models, LRP-1-deficient mice have higher
plasma FVIII levels,72 and blocking both LRP and HSPGs results in prolongation of the
FVIII half-life.71 Stabilin-2, expressed on liver endothelial sinusoidal cells, is also
involved in vWF dependent endocytosis of FVIII.68 Both FVIII and vWF are rapidly
degraded when they are bound by macrophages.73 Given the molecular weight of FVIII,
it could not be renally cleared by filtration in its intact form. In summary, FVIII is
synthesized in endothelial cells primarily in the liver, activated upon endothelial injury,
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inactivated spontaneously and by proteolysis and cleared by the reticuloendothelial
system in the liver.
Studies to support direct relationships between the complications of CKD and the
biochemistry of FVIII are lacking. Nevertheless, CKD may play a role in activation,
inactivation or non-renal clearance indirectly by affecting enzymatic reactions, LRP-1 or
immune function more generally. For example, metabolic acidosis is a common
complication of CKD and the pH of the blood is important for regulating protein
function. The dissociation of the A2 subunit of FVIIIa heavy chain is pH dependent in
vitro,62,74 such that at lower pH there is less dissociation and greater FVIIIa activity.62,74
Immune function is impaired in patients with CKD75 and more specifically, the uremic
toxin, P-cresyl sulfate, suppresses macrophage function.76 Since macrophage activity is
responsible for clearance of FVIII, CKD might lead to reduced FVIII clearance through
reduced activity of the reticuloendothelial system.75 The inflammatory cytokines
prominent in CKD, including TNF-alpha77 and IL-6,78 are also considered the main
mediators of inflammation-induced activation of the hemostatic system.79,80 Elevated
TNF-alpha mediates downregulation of protein C,81 the anticoagulant that inactivates
FVIII. Thus, higher levels of TNF-alpha in CKD may result in less inactivation of FVIII
and greater FVIII activity. IL-6 promotes transcription activation of FVIII,82 and in this
way CKD related IL-6 could lead to higher FVIII levels.
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Determinants of FVIII blood levels
vWF is an important determinant of plasma FVIII levels. vWF is synthesized in
endothelial cells and megakaryocytes as a pre-pro-polypeptide monomer of 2,813 amino
acids. Each monomer contains N- and O- glycosylation sites, which are involved in vWF
secretion and clearance.83 In endothelial cells, vWF is constitutively secreted mostly as
dimers, and is stored as larger multimers in Weibel-Palade bodies. In platelets, vWF is
stored in alpha-granules until platelets are activated.84 vWF multimers in the circulation
are long filamentous strands that are loosely coiled until activation causes them to
unwind and expose sites for platelet adhesion. There are two forms of vWF. High
molecular weight vWF functions to promote hemostasis through facilitating plateletplatelet interactions and platelet-subendothelium adhesion, as well as platelet
aggregation. Low molecular weight vWF functions to carry and protect FVIII from
activated protein C mediated proteolytic degradation or early activation by thrombin. The
vWF binding sites are located on the A3 domain of the light chain of FVIII. Interestingly,
there is reciprocal regulation; Factor VIII serves as a cofactor to ADAMTS13, a
metalloprotease that proteolytically cleaves large vWF multimers.85
ABO blood group, a genetic trait, is also a determinant of plasma FVIII levels,
primarily through ABO blood group effect on vWF. Twin studies indicate that
approximately 66% of the variation in plasma vWF is genetically determined, of which
30% is explained by ABO group.86 The ABO antigens are carbohydrate molecules
expressed on RBC membranes and other cells including epithelium, platelets and
vascular endothelium. N-linked sugars on vWF also contain ABO blood group
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determinants. Persons with blood group types A, B and AB (the non-O blood types) have
higher vWF and FVIII levels. The level of vWF increases across blood types:
O<A<B<AB. The level of FVIII also increases accordingly: O<A<AB<B. ABO type
appears to affect clearance rather than synthesis or secretion of vWF.87-89 The receptor
involved in ABO blood type facilitated clearance of vWF has not been identified. It has
been suggested that ADAMTS13 may play a role in clearance of vWF since
ADAMTS13-mediated proteolysis of vWF is much faster for O-blood group than non-O
blood group.90 This is thought to be due to impaired ADAMTS13 cleavage since the A
and B antigens are in close proximity to the ADAMTS13 cleavage site within the A2
domain.91 An experimental model of ADAMTS13-deficient mice however, failed to
support the role of ADAMTS13 in vWF clearance, but mice do not express ABO
antigens.
To understand whether FVIII and CKD might share common etiologic factors, we
cross-referenced published reports of genetic variants associated with both FVIII and
kidney disease. We did not identify any single nucleotide polymorphism (SNP) directly
linked to both kidney disease and FVIII or vWF. Rather, we identified common genes
important in kidney function or development and related to FVIII or vWF (Table 1.2.).
Some of these findings were incongruous. For example, rs4981021 located at STAB-2,
which encodes stabilin-2 protein, is associated with higher FVIII and lower vWF.
Deficiency of stabilin 1 and 2 in mice causes glomerulofibrosis, albuminuria and early
mortality. Other associations were congruous, such as a rs10102164 at SOX17, which is
associated with FVIII and vWF. SOX17 is expressed throughout the urogenital tract and
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mutations of which are associated with congenital anomalies of the kidney and urinary
tract. Different SNPs at SYNGR1 are associated with lupus, lupus nephritis and higher
vWF and FVIII. SYNGR1 encodes synaptogyrin1, which is an integral membrane protein
involved in vesicle trafficking and exocytosis. Genetic risk variants for kidney disease
may influence proinflammatory pathways that affect FVIII. For instance, APOL-1
genetic variants, which have a prevalence of 13% among African-Americans, are
associated with a five-fold higher risk of progressive kidney disease.92,93 APOL1 encodes
apolipoprotein 1 in macrophages, endothelial cells and epithelial cells and its expression
is induced by inflammatory cytokines. In the ARIC study, the relationship of FVIII and
ESKD varied by different APOL-1 risk variants. The HR (95% CI) of ESKD per IQR
change in FVIII was 2.48 (1.39, 4.41) for African-Americans with two APOL-1 risk
variants, 1.19 (0.92, 1.53) for African Americans with one risk variant or none, and 1.07
(0.83, 1.38) for European-Americans.94 The authors suggest that vascular injury might be
a common determinant that leads to inflammatory cytokines, which promotes higher
factor FVIII and APOL1 expression. rs4845625 at IL6R was associated with CKD in
Japanese, and is also associated with biomarkers of inflammation including IL6, TNFalpha and CRP, however FVIII and vWF were not tested.

Measurement of FVIII
As we describe the relationship of FVIII and CKD, a review of the means of
measurement of FVIII is warranted. FVIII can be measured by quantifying the amount of
antigen present or by determining its procoagulant activity. The most common way of
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measuring FVIII is the one-stage activity assay based on the activated partial
thromboplastin time (aPTT).95 In this assay, the length of time it takes for a patient’s
plasma to correct the clotting time of plasma known to be deficient in FVIII is measured.
This is compared to a reference plasma, with a value of 100% FVIII activity. The
patient’s FVIII activity is expressed as a percent of normal activity. The normal range in
healthy adults is 50-150%. This one-stage activity assay is used clinically to detect factor
deficiencies so the ability to detect low levels of FVIII are critical. However, given that
our interest in distinguishing higher levels of FVIII that might be associated with
increased thrombotic risk, the choice of an assay should address the ability to detect
modestly elevated values. Different methods were compared using samples with high
FVIII. The one-stage activity assay, the chromogenic activity assays and immunoassays
had similar intra-assay precision (CV 6-8%). Inter-assay precision was best with the
chromogenic assay (CV 13%) compared to the one-stage activity assay (CV 21.9%) and
the ELISA (CV 19.3%).95 The one-stage assay was affected by lepirudin, lupus
inhibitors, low-molecular weight heparin and unfractionated heparin; while the
chromogenic assay and immunoassay were unaffected by these factors. The majority of
studies relating FVIII and CKD measure FVIII activity. Of note, Factor VIII measured by
one-stage activity assay was highly correlated with FVIII measured by a two-stage
ELISA, r= 0.87.96 Biological variation of FVIII has been examined in short and longterms studies. Within individual variation was 4.8-11.4% (for repeated measures within a
week) and 15.8% (for repeated measures monthly across a year).97-99 There was no
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apparent difference in the mean values for FVIII activity throughout the day to suggest
that there is a circadian pattern to FVIII.98

1.6. Association of Factor VIII and Chronic Kidney Disease
Epidemiological studies of FVIII, vWF and CKD
Several cohort studies support an association of FVIII and kidney disease (Table
1.3.). In CHS, renal insufficiency, which was defined as a serum creatinine 1.3 mg/dL in
women and 1.5 mg/dL in men, was associated with higher mean (± SEM) FVIII (145 ±
2%) compared to those without renal insufficiency (131 ± 2%), among 5,888 older
adults.49 Using a more contemporary measure of kidney function, the Multiethnic Study
of Atherosclerosis (MESA) studied 6,751 self-identified Caucasian, Chinese, AfricanAmerican and Hispanic participants who were free of cardiovascular disease at the time
of study enrollment and had relatively preserved kidney function (mean eGFR
79ml/min/1.73m2).100 Factor VIII was inversely associated with eGFR; for every 10
ml/min/1.73m2 decrement in eGFR, FVIII was 2% (95% CI 1, 3) higher and vWF was
3% (95% CI 1, 5) higher. The British Regional Heart Study included 4,029 men age 4059 recruited from 1998-2000 with eGFR 15  70 ml/min/1.73m2.101 FVIII increased
across eGFR categories; median (IQR) FVIII was 131 (130, 133)% for eGFR  70, 132
(130, 133)% for eGFR 60-69, and 135 (133, 138)% for <60 ml/min/1.73m2, p-trend
<0.001. Two prospective cohort studies reported an association of baseline FVIII and
CKD risk. The ARIC study of 14,854 participants, demonstrated higher vWF and FVIII
in participants with CKD compared to those without CKD.102 In this study, the HR (95%
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CI) for incident CKD over a mean follow-up time of 14.5 years in the highest versus the
lowest quartile was 1.46 (1.26, 1.68) for vWF and 1.39 (1.20, 1.60) for FVIII. In MESA,
FVIII was also associated with rapid kidney function decline (defined as eGFR decline
>3 ml/min/year); the OR (95% CI) of rapid decline was 1.11 (1.03, 1.18) per standard
deviation (SD) higher FVIII.48 In summary, across a wide spectrum of ages above 40
years, mild to moderate kidney disease was associated with higher levels of FVIII, and
higher FVIII was also linked to progression of CKD.

Studies of FVIII, vWF and end-stage kidney disease
The association of FVIII and kidney disease has also been reported in ESKD and
in patients receiving maintenance dialysis, albeit in small studies and without adjustment
for covariates.103 Among 21 patients with kidney failure and 42 with kidney failure on
established hemodialysis, FVIII and vWF were 2-3-fold higher than normal adult
controls.104 Mean (± SD) FVIII was 233 ± 123% in kidney failure, 218 ± 10% in dialysis
and 79 ± 27% in controls and vWF was 247 ± 154% in kidney failure, 265 ± 159% in
dialysis and 94 ± 31% in controls.104 In an early study that compared FVIII in 38 patients
with kidney failure, 19 hospitalized patients with normal kidney function and 17 normal
subjects, FVIII was elevated in both patient groups, and mean FVIII was significantly
higher in those receiving dialysis versus non-dialytic (conservative) treatment.105 Not all
reports agreed with these findings; in a study of 57 patients with kidney failure, 49
patients with normal kidney function and 8 with impaired kidney function, the authors
failed to find a correlation between vWF and FVIII and kidney function.106 Given the
20

individual variability in FVIII, a comparison of FVIII in the same patients before and
after dialysis might clarify if commencing maintenance dialysis is associated with lower
FVIII. In 16 patients with chronic kidney failure who later started dialysis, mean (± SEM)
FVIII was significantly lower after being established on dialysis: FVIII was 279 ± 36% in
chronic kidney failure versus 218 ± 28% in established dialysis, p <0.05. Mean vWF was
not significantly different.104 A more recent study reported FVIII and vWF were elevated
prior to starting dialysis and by six months mean FVIII and vWF were greatly reduced.107
The hemodialysis procedure may affect FVIII differently than vWF. In ten patients
studied immediately before and after receiving dialysis, FVIII increased in some and
decreased in others, while vWF levels were increased following dialysis.103 vWF also
increases with duration of the dialysis procedure.104 As endothelial cells release both
vWF and FVIII, whereas platelets release vWF but not FVIII, increased vWF in dialysis
may be due to platelet activation as the blood comes in contact with the extracorporeal
circuit in hemodialysis. There are fewer studies in peritoneal dialysis, but they support a
similar pattern. Among 14 patients receiving continuous ambulatory peritoneal dialysis
Factor VIII and vWF were significantly greater (301 ± 122% and 372 ± 112%,
respectively) than in ten normal controls (101 ± 11%, and 99 ± 7%, respectively).108
Small studies of kidney transplant recipients indicate that FVIII109 and vWF levels
are elevated in the early post-transplant period.103 As in the studies of FVIII and vWF in
dialysis patients, there was no adjustment for covariates. In a study of 17 consecutive
deceased donor kidney transplant recipients on cyclosporine immunosuppression, pretransplant FVIII activity was 224%, FVIII antigen was 248% and vWF was 206%. These
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measures increased transiently to 360% for FVIII activity, 398% for FVIII antigen and
362% for vWF. By four months post-transplant they returned to pre-transplant levels.110
Similar findings were reported in eight kidney transplant patients before and 4 weeks post
transplantation.109 Another small study of 11 patients with functioning kidney transplants,
the reported mean FVIII (± SD) was 179 ±100 and vWF (±SD) was 136 ±64 six months
to 6 years post-transplant. These values were similar to FVIII and vWF in hemodialysis
patients.103 Despite presumed restoration of kidney function, FVIII levels are not returned
to a normal range, perhaps due to immunosuppressive agents related prothrombotic
effects or endothelial damage.

Epidemiology of FVIII, vWF and albuminuria or proteinuria
Albuminuria, which is a marker of endothelial dysfunction111 as well as kidney
disease, is associated with elevated levels of FVIII and vWF. In an early study of 57
patients with diverse forms of kidney disease, vWF and FVIII were positively correlated
with magnitude of proteinuria.106 These findings were confirmed in two other
studies,112,113 and this relationship between higher ACR and higher vWF levels, vWF
activity and FVIII persisted after adjustment for risk factors.113 Among type 1 diabetics,
vWF was elevated in those with albuminuria (ACR  30 mg/g) and/or reduced GFR
(eGFR<60 ml/min/1.73m2) as compared to those without albuminuria.114 For every 88.5
mg/g increase in UACR, the vWF and FVIII levels were 8.3% and 6.3% higher. In
nephrotic syndrome where proteinuria exceeds 3.5 grams per day, vWF was much higher
(287 ± 26%) than in controls (99 ± 5%), and this was independent of presence of chronic
22

renal failure.115 The relationship between FVIII and albuminuria may differ by
race/ethnicity. In a study of 1,051 self-identified, African-Americans and 894 nonHispanic whites with hypertension, albuminuria was associated with higher FVIII and
vWF in African-Americans, but not in non-Hispanic whites.116

FVIII and vWF in different etiologies of CKD
If there were distinct patterns of FVIII in different etiologies of kidney disease,
independent of kidney function, this might indicate that FVIII elevation in kidney disease
represents the underlying pathology of the kidney disease. There are only a few studies
that address the relationship of kidney disease etiology and FVIII or vWF. The studies
are limited by small sample size and lack of control for eGFR, albuminuria and other
important covariates. In one study of 105 patients, vWF was higher in minimal change
disease compared to membranous nephropathy or focal segmental glomerulonephritis
among primary renal disorders, and vWF was higher in lupus and amyloid compared to
Alport’s syndrome or mixed cryoglobulinemia among secondary causes of
glomerulonephritis.112 A second study confirmed that vWF was higher in nephrotic
syndrome, and noted it was also higher in lupus nephritis and hypertensive nephropathy
compared to diabetic nephropathy and chronic glomerulonephritis,117 but a third study
reported vWF was higher in lupus nephritis compared to nephrotic syndrome.118 Among
non-insulin dependent diabetic patients, there is a heterogenous relationship of vWF to
albuminuria, which is dependent on the kidney pathology.119 Patients with typical
diabetic nephropathy changes had higher levels of vWF compared to those with more
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atypical biopsy findings, such as advanced tubulointerstitial fibrosis. This study supports
the concept that the underlying kidney pathology is related to vWF. The data exploring
the etiology of kidney disease in relation to FVIII in dialysis patients is conflicting. In
one study, Factor VIII levels did not differ between non-diabetic and diabetic
hemodialysis patients, although FVIII activity was twice that of healthy controls.120 In a
more recent study of 37 CAPD patients, mean (± SE) FVIII and vWF were significantly
higher in diabetics (195 ± 4% and 169 ± 5%) compared to non-diabetics (159 ± 5% and
124 ± 9%).121 Larger studies are needed to determine whether kidney disease etiology
influences FVIII.

ADAMTS13 and CKD
There is growing evidence to support a relationship between ADAMTS13 and
CKD etiology as well as kidney function. Among type 1 diabetics, kidney function was
positively correlated with ADAMTS13 antigen and activity; ADAMTS13 activity was 95
± 16% in controls, 104 ± 20% in mild CKD, and 108 ± 19% in severe CKD.122
ADAMTS13 levels are also reduced in dialysis patients compared to controls; median
(IQR) ADAMTS13 was 279 (238-329) ng/mL in HD patients and was 578 (486-690)
ng/mL in controls.123 vWF levels are elevated and ADAMTS13 levels are reduced in a
variety of etiologies of CKD including lupus nephritis, nephrotic syndrome, diabetic
nephropathy and chronic glomerulonephritis compared to normal controls.118,124 In
acquired or genetic deficiency of ADAMTS13, ultra-large multimers of vWF accumulate
resulting in platelet aggregation and microthrombi. This clinical syndrome known as
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thrombotic thrombocytopenia purpura (TTP) can be life-threatening and not uncommonly
causes acute kidney failure. It is not known outside of TTP if lower levels of
ADAMTS13 cause CKD, although one study reported that higher vWF:ADAMTS13
ratio is associated with a decline in kidney function.125

Prospective studies of ABO, FVIII and CKD
There is growing evidence linking ABO blood group to cardiovascular diseases.
For instance, in a US study the risk of stroke was increased in blood type AB,
independent of FVIII and typical stroke risk factors.126 In the same cohort, blood type AB
was also associated with incident cognitive impairment , with only part of the association
attenuated by FVIII.127 There is considerable data linking non-O blood groups and risk of
coronary artery disease128 and VTE.129-132 Non-O blood type is associated not only with
higher levels of vWF and FVIII but also several inflammatory cytokines that are related
also to VTE risk, including sICAM-1,133 IL6, TNF-alpha, e-selectin134,135 and pselectin.133,135 Thus ABO blood type may have an effect on VTE independent of vWF
and FVIII.
The literature on ABO blood type as it relates to CKD is scarce. A few small
studies compare the prevalence of ABO blood groups in CKD and ESKD using healthy
donors as a comparison group (Table 1.4.). None of the published reports account for
FVIII. In the US, veteran patients with CKD had blood group B more frequently and
blood group O less frequently than healthy controls.136 In a German study of different
etiologies of CKD, Blood group A was more prevalent among females with
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pyelonephritis, than blood type O, but there were no differences among males.137 A crosssectional study of 195 Brazilian hemodialysis patients and 80 healthy subjects,
demonstrated no significant differences in ABO blood group distribution between
patients and controls.123 In 231 Syrian hemodialysis patients, Blood group B was more
common and A was less common in dialysis patients than blood donors.138 The sum of
the literature suggests that B and AB are more common and O and A are less common in
dialysis patients, but larger prospective studies are necessary to confirm the possible
relationship between ABO blood group and kidney disease.

Hemophilia and kidney function
Several lines of evidence report that hemophilia might be protective against CKD.
Hemophilia A is an X-linked disorder caused by mutations in the FVIII gene and results
in low or absent FVIII. Given that higher FVIII is related to kidney disease, lower FVIII
might be associated with less kidney disease. Two cross-sectional studies showed that
people with severe hemophilia had higher kidney function than those with mild or
moderate hemophilia.139,140 In a study of 532 hemophiliacs, the reported prevalence of
CKD was 5.5%, which is less than the prevalence of CKD in the general US population.
The study sample had a median age 52 (range 40-98), but there was no comparison group
and CKD prevalence rates were not reported separately for Hemophilia A and B.140 A
third study of 3,422 hospitalized hemophilia patients (79% Hemophilia A) found that
CKD was a discharge diagnosis in just 31 patients. There was no association between
CKD and severity of hemophilia; the OR of CKD with severe versus mild/moderate
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hemophilia was 0.7 (95%CI 0.3-1.7), after multivariable adjustment.141 While these
studies suggest that hemophilia may be associated with better kidney function, they are
not conclusive.

1.7. Research gaps and future directions
While there is data to support a relationship of CKD and FVIII several questions
remain. First, is FVIII elevated due to consequences of CKD or does FVIII cause CKD?
Studies that describe this association are for the most part limited to a single
measurement of FVIII and kidney function, which limits our understanding of how FVIII
might influence kidney function and vice-versa. Second, are different etiologies of CKD
associated with different levels of FVIII? Studies addressing this issue are small, present
conflicting results and do not control for important covariates or kidney function.
Identifying the etiology of CKD is not straightforward, however, as biopsies are not
performed routinely and are not always conclusive. Accumulating sufficient biopsyproven cases to compare FVIII levels across a range of CKD etiologies would be
difficult. Third, do CKD and FVIII share similar genetic predisposition, including but not
limited to the potential impact of ABO blood type? Finally, as FVIII appears to mediate
the association of CKD and VTE, could efforts to lower FVIII reduce the risk of VTE?
Future research should aim to characterize the mechanisms of elevated FVIII
activity in CKD and assess the directionality of the relationship of FVIII and CKD,
including evaluation of potential confounders and common predictors. For instance, ABO
blood type might lead to CKD in addition to its impact on FVIII levels, but this has not
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yet been studied prospectively. A focus on macrophage clearance of FVIII in CKD versus
non-CKD might help elucidate if immune function is critical to this relationship.
Investigations on the impact of specific uremic toxins, such a P-cresyl sulfate, on
coagulation and inflammatory pathways, including effect on proteins critical for
coagulation, are currently lacking.

1.8. Conclusions
CKD is an emerging risk factor for venous thromboembolism. The mechanisms of
the association of kidney disease and VTE are understudied, but new evidence supports
FVIII as a mediator. FVIII activity is inversely correlated with kidney function from mild
to severe kidney disease, and remains high in dialysis and kidney transplantation. vWF
and ABO blood group are recognized determinants of FVIII, and are also linked to CKD.
A greater understanding of the pathophysiological mechanisms for higher FVIII in CKD
is necessary, and could lead to discoveries that would improve FVIII levels and reduce
VTE in CKD.
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Table 1.1.: Case-control and cohort studies of Chronic Kidney Disease and Venous Thromboembolism
Country,
Study design,
N participants Patient
Measure of
Findings HR or OR (95% CI)
Recruitment name
characteristics
kidney disease
period
Netherlands
Cohort, Tromso32
3,251
Age 25-84
Cystatin C
HR 2.5 (1.27, 4.96) for top vs bottom quartile of
1994-1995
cystatin C
USA
Cohort, ARIC33
10,700
Age 53-75;
Cystatin C based
HR 1.40 for eGFR 60-89, 1.94 for eGFR 15-59
1987-1989
White (n=8,317) and eGFR
compared to eGFR >90 ml/min/1.73m2
African-American
No association of creatinine based eGFR and VTE
(n=2353)
USA
Cohort, LITE6
19,073
Mean age 59 yrs;
Creatinine-based
HRs 1.29 (1.02, 1.62) for eGFR 60-89 and 1.71
75% white
Cystatin C
(1.18, 2.49) for eGFR 15-59 compared to eGFR90
ml/min/1.73m2
No association of cystatin C and VTE
USA
Cohort,
30,239
Age 45 and older;
Creatinine-cystatin HRs 1.28 (0.94, 1.76) for eGFR 60-90, 1.30 (0.77,
2003-2007
REGARDS7
46% male; 60%
C based
2.18) for eGFR 45-60 and 2.13 (1.21, 3.76) for
white, 40% black
ACR
eGFR <45, compared to eGFR 90 ml/min/1.73m2.
No association of ACR w VTE
Netherlands
Case-control,
2936 controls,
Age 18-70; cases
Creatinine-based
OR 1.2 (1.0, 1.4) for eGFR 60-90, 2.2 (1.5, 3.0) for
1999-2004
MEGA29
2473 cases
46% male
eGFR
eGFR <>90 ml/min/1.73m2
35
Denmark
Case-control
128,096 cases,
Hospitalized
Creatinine-based
OR 1.27 (1.10, 1.47) for hypertensive nephropathy
1980-2010
624,426
patients; cases 47%
eGFR (MDRD)
and 2.17 (1.68, 2.80) for nephrotic syndrome
controls
male
compared to healthy controls
Europe &
Meta-analysis,4
1,178 events,
97% white, 47%
Creatinine-based
HRs 1.29 (1.04, 1.59) for eGFR 75), 1.31 (1.00,
USA
Tromso, ARIC,
95,154
male across 5 studies eGFR
1.71) for eGFR 60, 1.82 (1.27, 2.60) for eGFR 45,
CHS, HUNT2,
participants
1.95 (1.26, 3.01) for eGFR 30, compared to eGFR
PREVEND
100 ml/min/1.73m2.
ACR
HRs were 1.34 (1.04, 1.72) for ACR 30, 1.60 (1.08,
2.36) for ACR 300 and 1.92 (1.19, 3.09) for ACR
1000 mg/g, compared to ACR 5.0 mg/g.
Netherlands
Cohort,
40,856
99% white; 50%
ACR
HR2.0 for ACR 30-300mg/g compared to ACR <30
PREVEND5
male
mg/g

Table 1.2.: Genes and SNPs associated with Factor VIII and vWF and Kidney Disease
Gene
Protein function
Association with FVIII or vWF
APOL1

Apolipoprotein L1 is a minor apoprotein of
HDL with a role in innate immunity
(trypanolytic factor) and possibly the
inflammatory response.

SOX17

SOX17 is a transcription factor essential for
endothelial cell morphogenesis, necessary
for function of stable endothelial cells,142
expressed throughout urogenital tract and
regulates beta-catenin signaling. SOX17 is
also a potent Wnt-signaling antagonist.143
Transmembrane protein that is associated
with urate levels.

TMEM171

30
STAB-2

SYNGR1

Interleukin
6 receptor
(IL6R)

Stabilin 2 protein, large transmembrane
receptor protein with potential functions in
angiogenesis, receptor scavenging, cell
adhesion, lymphocyte homing, endocytosis
of AGE modified proteins
Synaptogyrin1 integral membrane protein
associated with presynaptic vesicles in
neuronal cells and may have a role in vesicle
trafficking, synaptic machinery and
exocytosis.
IL6 promotes transcription of FVIII and
regulates inflammation

Association with Kidney disease

FVIII is associated with ESKD and
APOL1 risk alleles modify this
association. If both APOL1 risk alleles are
present, FVIII is associated with two-fold
risk of ESKD, but is only one risk allele or
none are present FVIII is not associated
with ESKD.94
rs10102164 is associated with FVIII p=2.4
x 10-9 and vWF p=2.9 x10-3. 144 It is
unknown how SOX17 might regulate
FVIII or vWF.

APOL1 risk alleles (rs73885319 and
rs60910145 are referred to as G1 and in perfect
linkage disequilibium; rs71785313 is referred
to as G2) are associated with seven-fold
increased risk ESKD in blacks G1 p=1.1 x 1039
and G2 p=8.8 x 10-18 if both risk alleles are
present compared to none.93
SOX17 mutations are associated with
duplication of urinary tract, vesico-ureteric
reflux, is associated with congenital anomalies
of kidney and urinary tract (CAKUT).143

rs548630 is associated with vWF
p=1.2x10-10 and FVIII p= 2.1 x 10-10.145
TMEM171 in regulating vWF and FVIII is
unknown, but it is associated with higher
basal vWF and secretion of vWF under
stimulus.
rs4981021 is associated with FVIII, p=3
x10-20 and vWF p=6 x 10-41.145
rs4981021 serves as proxy for rs12229292
(r2 = 0.879) and is associated with higher
FVIII and lower vWF.144
rs5750823 is associated with FVIII p=1.5
x10-6 and vWF p= 6 x10-14.145 SYNGR1 is
associated with higher basal vWF.

Rs17632159 is associated with serum urate
levels p=3.5 x 10-11 and gout OR 0.91 p=6 x103 146
. rs17632159 is associated with systolic
and diastolic BP.147
Frequency A1 0.31. effect for serum urate 0.039.
Deficiency of Stabilin 1 and 2 in mice causes
glomerulofibrosis, albuminuria and early
mortality.148
No GWAS linking specific SNPs to kidney
disease.
rs61616683 is associated with lupus in East
Asians Pmeta 5.73 x 10-10 and lupus nephritis in
Chinese149,150

rs 4845625 (in full linkage disequilibrium
with rs6689393) and other variants in
IL6R are associated with biomarkers of
inflammation including C-reactive protein,
fibrinogen, soluble IL6R, IL6, IL8, TNF-

rs4845625 identified as candidate gene given
association of CAD in GWAS in whites, was
significantly related to CKD in cross-sectional
study of 2247 Japanese (1,588 of whom had
CKD defined as eGFR<60 ml/min/1.73m2).152

alpha.151
RAB27A
STXBP5

PLA2R1

Rab GTPases regulate intracellular
membrane traffic.153 Rab27A is recruited to
weibel-palade bodies, where vWF is stored
in endothelial cells. Rab27a and its effector
slp4-a regulate apical transport of Rab27
bearing vesicles in polarized renal epithelial
cells and control cell size.154
PLA2R is a type 1 transmembrane receptor
that binds and removes secreted PLA2
enzyme from circulation. PLA2 is
proinflammatory.

Rab27a regulates vWF release from
endothelial cells. STXBP5 promotes
weibel-palade body exocytosis by
interaction with Rab27a effector
slp4a.155Silencing STXBP5 impairs vWF
secretion. rs9390459 (near STXBP5) is
associated with higher vWF and FVIII.144
sPLA2-IIA correlates with FVIII and
vWF157 but there are no identified
PLA2R1 SNPs associated with FVIII and
vWF.

rs1528472 (near RAB27a) is associated with
proteinuria in adults, p=5 x 10-7. 156

rs17830558, PLA2R1, OR = 2.2, P =1.9 × 10 8 158
. The gene encoding PLA2R is expressed in
podocytes and is the target of auto-antibodies
responsible for ~70% idiopathic membranous
nephropathy, a type of nephrotic syndrome.159
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Table 1.3.: Cross-sectional and Cohort studies on Factor VIII and Chronic Kidney Disease
Study year,
Study design
N patients
Biomarker
Findings
country
2003, US
Cohort study,
5,888 older adults
FVIII activity
FVIII was higher in CKD adjusting for age, sex, race, education,
CHS49
cross-sectional
CKD defined as SCr >DM, HTN, SBP, DBP, triglycerides, smoking, alcohol, physical
analysis
1.3 mg/dL in women,
activity, BMI, CVD.
1.5 mg/dL men
2006, UK
Cohort study,
4,029 adults age 60-79
FVIII activity,
FVIII and vWF were higher across categories of eGFR >=70, 60-70,
Cohort, British cross-sectional
vWF Antigen
<60, adjusting for age, DM, HTN, CVD, SBP, HDL, BMI, LVH,
Regional Heart analysis
alcohol, smoking, physical activity.
Study101
2009, US
Cohort study,
14,854 middle age adults
FVIII activity,
FVIII and vWF were associated with incident CKD, adjusting for
Cohort,
prospective
from 4 different US
vWF Antigen
age, sex, race, DM, SBP, antihypertensive use, CVD, smoking,
ARIC102
analysis
communities
alcohol use, TG, HDL, LDL, baseline eGFR.
FVIII more strongly associated with CKD among those with DM vs
without DM (p ixn <0.01).
2011, US
Cohort study,
6,751 adults free of CVD FVIII activity,
FVIII and vWF were higher in lower eGFR, adjusting for age, sex,
Cohort,
cross-sectional
at entry
vWF Antigen
race, income, study site, smoking, alcohol, BMI, DM, HTN, statin
MESA100
analysis
Reference group: eGFR
use, ACE-I, LDL, HDL, TG, fasting glucose and
cystatin C >90
ln(albumin/creatinine).
ml/min/1.73m2
2012, US
Cohort study,
4,966 adults free of CVD FVIII activity
FVIII was associated with renal decline, and rapid decline, adjusting
Cohort,
prospective
at entry
for age, sex, race, DM, HTN, HDL, LDL and albuminuria.
MESA48
analysis
2014,
Case-control,
2,936 controls.
FVIII activity,
FVIII, vWF were higher in eGFR<1st percentile (eGFR <53) vs ref.
Netherlands
cross-sectional
Reference group: eGFR
vWF antigen
FVIII and vWF were higher with lower eGFR, adjusting for age and
MEGA study29 analysis
>86 (50th percentile)
sex.
2018, US,
REGARDS30

Case-Cohort
949 cohort random
FVIII antigen
FVIII was higher in lower eGFR, adjusting for age, sex, race, BMI,
study, crosssample
DM, HTN, CVD, hyperlipidemia, and smoking.
sectional
Abbreviations: HTN hypertension; DM diabetes; CVD cardiovascular disease, SBP systolic blood pressure; BMI body mass index; LVH left ventricular
hypertrophy; ACE-I angiotensin converting enzyme inhibitor; LDL low density lipoprotein; HDL high density lipoprotein, TG triglycerides;

Table 1.4.: Distribution of ABO blood groups in hemodialysis patients and controls
Study
N patients
A
B
AB
country
Syria138
US136

231 hemodialysis patients
11,320 blood donors*

71 (30.7)
4,528 (40)

34 (14.7)
906 (8)

33

184 CKD patients including dialysis 75 (40.8)
27 (14.7)
37 dialysis patients
12 (32.4)
9 (24.3)
3,820 blood donors*
1540 (40.3)
325 (8.5)
Brazil123 195 hemodialysis
60 (30.8)
28 (14.3)
80 healthy controls
28 (35)
8 (10)
Jordan160 197 kidney failure
90 (45.7)
34 (17.3)
No controls
Iran161
151 hemodialysis patients
55 (34.6)
26 (17.2)
No controls
Iraq162
60 hemodialysis patients
6 (10)
15 (25)
No controls
Total
871 dialysis and kidney failure
294 (33.8)
146 (16.8)
patients
*Number of blood donors per blood group inferred from total percentage reported.

O

Reported differences in
frequencies among patients and
controls
B more common in dialysis, A
less common in dialysis
compared to donors
B more common in renal patients,
O less common compared to
donors
No significant differences

8 (3.5)
566 (5)

118 (51.1)
5320 (47)

6 (3.3)
135 (3.5)
9 (4.6)
7 (8.8)
13 (6.6)

76 (41.3)
16 (43.2)
1820 (47.6)
98 (50.3)
37 (46.2)
60 (30.4)

62 (41)

8 (5.3)

No comparison group

6 (10)

33 (55)

No comparison group

98 (11.3)

333 (38.2)

No comparison group

CKD

Increased Procoagulants
Decreased Anticoagulants
Platelet activation/aggregation
Decreased fibrinolytic system
Enhanced Inflammation

VTE

Figure 1.1.: Potential mechanisms of Venous Thromboembolism in Chronic Kidney
Disease
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Figure 1.2.: Potential explanations for elevated Factor VIII in Chronic Kidney
Disease
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2.1. Abstract
Background: Kidney disease has been associated with venous thromboembolism (VTE)
risk, but results conflict and there is little information in blacks.
Study design: Prospective cohort study
Setting & participants: 30,239 black and white adults age 45 and older enrolled in the
Reasons for Geographic and Racial Differences in Stroke (REGARDS) study between
2003-7.
Predictors: Estimated GFR using the combined creatinine-cystatin C (eGFRCr-CysC)
equation and urinary albumin-creatinine ratio (ACR).
Outcomes: The primary outcome was adjudicated VTE and secondary outcomes were
provoked and unprovoked VTE separately. Mortality was a competing risk event.
Results: Over 4.6 years of follow-up, 239 incident VTE events occurred over 124,624
person-years. Cause-specific hazard ratios (HRs) of VTE were calculated using
proportional hazards regression adjusted for age, sex, race, region of residence and body
mass index. The adjusted VTE HRs (95% CI) for eGFRCr-CysC 60-<90, 45-<60 and <45
versus ≥90 ml/min/1.73m2 were 1.28 (0.94, 1.76), 1.30 (0.77, 2.18) and 2.13 (1.21, 3.76).
The adjusted VTE HRs (95% CI) for ACR 10-<30, 30-<300, >300 vs <10mg/g were 1.14
(0.84, 1.56), 1.15 (0.79, 1.69) and 0.64 (0.25, 1.62). Associations were similar for
provoked and unprovoked VTE.
Limitations: Single measurement of eGFR and ACR may have led to misclassification.
Smaller numbers of events may have limited power.
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Conclusions: There was an independent association of low eGFR (<45 vs ≥90) with
VTE risk, but no association of ACR and VTE.
2.2. Introduction
Chronic kidney disease (CKD) affects 13% of the general population1 and is a
strong independent risk factor for death and cardiovascular disease including stroke,
coronary disease, heart failure and peripheral arterial disease.2 There is an increased risk
of venous thromboembolism (VTE) in nephrotic syndrome,3 in patients receiving
maintenance dialysis,4 and in renal transplant recipients5,6 but the risk of VTE in patients
with earlier stages of CKD is unclear.7-9 VTE consists of deep vein thrombosis (DVT)
and pulmonary embolism (PE) and is the third leading vascular disease in the U.S.,
affecting approximately 500,000 Americans each year and contributing to >100,000
deaths annually.10 Prior studies linking measures of kidney function and VTE conflict,
possibly due to varying composition and limited statistical power or the use of different
measures of kidney disease in these studies, including various equations for estimated
glomerular filtration rate (eGFR) and definitions of albuminuria.
To better elucidate the relationship between CKD and VTE, we assessed the
associations of kidney disease measures with incident VTE in the Reasons for
Geographic and Racial Differences in Stroke (REGARDS) study. We had four primary
aims. First, to determine the association of albuminuria and eGFR, in particular eGFR
based on combining creatinine and cystatin C (eGFRCr-CysC), and VTE in the REGARDS
study. Second, because results of prior studies disagreed as to whether CKD is more
strongly associated with unprovoked or provoked VTE9,11 (which refers to VTE preceded
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within 90 days by major trauma, surgery, or marked immobility or associated with active
cancer or chemotherapy), we evaluated associations of kidney disease measures with
each VTE type. We hypothesized that the association would be larger for provoked than
unprovoked VTE because persons with CKD might be more likely to be hospitalized and
require surgery. Third, since prior studies had limited numbers of black participants, and
CKD disproportionately affects blacks, we sought to evaluate whether race modified the
association of CKD and VTE. Finally, to contextualize the importance of CKD with
regards to VTE risk, we compared the population attributable fraction for a range of
kidney function to that of older age and obesity, which are established VTE risk factors.

2.3. Methods
Study population and design:
We studied participants in the REGARDS study, a prospective, nationally representative
cohort study of blacks and whites in the US, which has been previously described.12
REGARDS enrolled 30,239 black and white men and women age 45 and older between
2003-2007. Due to the goals of REGARDS to assess black-white disparities in stroke and
cognitive decline, only self-identified non-Hispanic white and black individuals were
included. Additional exclusion criteria included medical conditions preventing long-term
participation, active cancer, active treatment for cancer, residence in or awaiting
placement in a nursing home, or inability to communicate in English. For this analysis we
excluded participants who had baseline VTE, were missing measures of kidney disease,
or who reported being on dialysis.
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Participants were identified from commercially available lists of residents and
recruited through a mailing followed by telephone contact (response rate 33%). Of
eligible participants contacted, the cooperation rate was 49%, similar to many other
cohort studies. Participants first completed a computer-assisted telephone interview for
self-reported demographic, risk factor and medications data. Then they underwent an inhome visit at which written informed consent was obtained, and anthropomorphic data,
medication inventory, urine samples and fasting phlebotomy were performed. During the
in-home examination, standardized protocols were followed to obtain 2 blood pressure
measurements that were averaged for analysis, an electrocardiogram (ECG), height and
weight. Blood and urine samples were collected after a 10 to 12 hour fast. Blood was
centrifuged locally, and shipped with the urine samples on ice packs to the University of
Vermont Laboratory for Clinical and Biochemistry Research for reprocessing and
analysis or storage.13 The study was approved by all institutional review boards at
participating universities, University of Alabama IRB 00000726, University of Vermont
CHRMS 00-295.

Laboratory methods:
Serum creatinine was measured using an isotope-dilution mass spectrometry–
traceable method14 using the Vitros 950IRC instrument (Johnson & Johnson Clinical
Diagnostics, Rochester, NY), with a coefficient of variance (CV) of 1.1%. Urinary
albumin was measured with the BN ProSpec nephelometer (Dade Behring, Marburg,
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Germany) with CV of 2.2% at 110 mg/L and 4.3% at 13 mg/L. Urinary creatinine was
measured with a rate-blanked Jaffé procedure, using the Modular-P analyzer
(Roche/Hitachi) with CV of 2.6% at 66 mg/dL and 8.6% at 156 mg/dL. Serum cystatin C
was measured with high sensitivity particle-enhanced immunonephelometry (N Latex
Cystatin C on the BNII, Dade Behring, Deerfield, IL), with an intra-assay CV of 2.02.8% and an inter-assay CV of 2.3-3.1%.

Definitions:
eGFR was calculated using the CKD-EPI equations based on creatinine
(eGFRCr), cystatin C (eGFRCysC) and combined creatinine-cystatin C (eGFRCr-CysC).15
eGFR was categorized as <45, 45-<60, 60-<90, ≥90 ml/min/1.73m2 to correspond to
clinical categories. Urinary albumin to creatinine ratio (ACR) was categorized as <10,
10-<30, 30-<300, ≥300 mg/g.
Covariates of interest were obtained at baseline and included age, sex, race (selfreported as black or white), region of residence (southeast or non-southeast), body mass
index (BMI) in kg/m2, hypertension, diabetes, hyperlipidemia, cardiovascular disease
(CVD), smoking, self-report of current postmenopausal hormone therapy (HT), aspirin
(ASA), statin or warfarin use. Hypertension is deﬁned as systolic blood pressure >140
mm Hg and/or diastolic blood pressure >90 mm Hg and/or use of antihypertensive
medication. Diabetes is deﬁned as fasting glucose >126 mg/dL, non-fasting glucose >200
mg/dL, or use of diabetes medication. Hyperlipidemia was defined as cholesterol >240
mg/dL or low density lipoprotein >160 mg/dL or taking medications for high cholesterol.
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CVD was defined as a self-report of pre-baseline myocardial infarction, aortic aneurysm,
stent, coronary artery surgery or stroke.

Identification and validation of outcomes:
The primary outcome was incident VTE, ascertained as previously described.16
In brief, medical records were obtained from potential VTE events, each of which was
reviewed by two physicians and major disagreements settled by a blinded third
reviewer.16 Provoked VTE was defined as a VTE that was preceded within 90 days by
major trauma, surgery, or marked immobility or associated with active cancer or
chemotherapy. All other events were considered unprovoked. The competing event of
death was identified through active surveillance including calls to participants, search of
online sources e.g. Social Security Death Index and National Death Index. Further details
of ascertainment were previously reported.17,18

Statistical Analysis:
We compared baseline characteristics among participants across eGFRCr-CysC
and ACR categories using ANOVA for continuous variables and χ2 tests for categorical
variables. Dichotomous variables were expressed as percentages and continuous variables
as means ± standard deviation (SD).
We calculated age, sex and race adjusted incidence rates of VTE per 1000
person-years with 95% confidence intervals (CI) for each kidney disease measures using
Poisson regression. We used Cox proportional hazards regression to estimate cause53

specific hazard ratios (HRs) with 95% CI for the competing risk of VTE and mortality.
The observation time was defined as time from completing the baseline in-home visit to
time of lost to follow-up, end of follow-up or event. Participants were censored for death
in the VTE model, and censored for VTE for the mortality model.19 To control for
confounding we created a multivariable model including demographics (age, sex, race,
region of residence) and established VTE risk factors (BMI) to adjust associations of
kidney disease measures and VTE. An interaction of race x region for VTE risk was
previously reported in REGARDS so this interaction term was included in the model.16
The same covariates were used to estimated adjusted HRs for provoked and unprovoked
VTE. Mortality models were additionally adjusted for hypertension, diabetes,
hyperlipidemia, history of cardiovascular disease and smoking. Violations of the Cox
proportional hazards model assumptions were assessed by visual inspection of the logminus-log survival plots and by testing global and individual Schoenfeld residuals. We
tested for interactions among kidney disease measures and race (black/white), adjusting
for age, sex and BMI, and stratified by region to account for known interaction between
race and region. We also tested for an interaction between eGFR and ACR.
In a secondary analysis, we estimated the HR and 95% CI for VTE using
eGFRCr, eGFRCysC using the CKD-EPI equation and eGFRCr using the Modification of
Diet in Renal Disease (MDRD) equation to understand whether a difference in estimating
equations could account for conflicting reports in the association of kidney disease
measures and VTE.
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We calculated the population attributable fraction (PAF) of CKD (using a range
of eGFRCr-CysC cut points <45, <60 and <90 ml/min/1.73m2), age ≥65 versus <65 years
and obesity (BMI>30m/kg2 vs <30 kg/m2) for VTE using the punafcc command in Stata.
To reconcile our null findings with the literature showing an association of
albuminuria and VTE we performed a post-hoc sensitivity analysis using estimated
albumin excretion rate (AER), which is the product of ACR and estimated creatinine
excretion rate (eCER), using Ix’s formula.20
eAER= ACR * (879.89 + 12.51*weight(kg) – 6.19*Age + (34.51 if black) –
(379.42 if female) )

Statistical significance was considered as a two-tailed P<0.05, and for interaction
analyses p<0.10. All statistical analyses were performed by the use of Stata software
version 14 (StataCorp LP).

2.4. Results
The initial cohort included 30,239 participants. After exclusions for missing
baseline home visit or follow-up data (n=684), self-report of dialysis (n=113) or baseline
VTE (n=1,741), there were 27,703 participants. A total of 2,601 participants (8.6% of
initial cohort) were missing any kidney disease measure with the following mutually
exclusive counts: serum creatinine (n=1,871), serum cystatin C (n=2,518), urine albumin
(2,002) and urine creatinine (n=1,929). The final analysis included 25,102 participants
(Figure 2.1.).
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The analytic cohort was 54% female, 40% black, and 48% age 65 or older.
There were 9% with eGFRCr-CysC <60ml/min/1.73m2, 11% with eGFRCr
<60ml/min/1.73m2, 15% with eGFRCysC <60ml/min/1.73m2 and 14% with ACR
>30mg/g. There were 50 participants with ACR>3000mg/g and only one VTE occurred
in this category.
Compared to those with higher eGFRCr-CysC at baseline, participants with lower
eGFRCr-CysC were older, more likely to have hypertension, diabetes, hyperlipidemia, be a
former or never smoker, and use statins, aspirin or warfarin (Table 2.1.). For higher
compared to lower ACR categories, diabetes, hypertension, CVD, current smoking were
more common (Table 2.2.).
There were 239 VTE events (113 unprovoked, 126 provoked) during 124,624
person-years follow-up. The incidence rates of VTE with 95% CI are shown in Table 2.3.
and increased monotonically across categories of declining eGFRCr-CysC. The incidence
rates of VTE increased across categories of ACR except for the highest category (
300mg/g), where the number of events was limited. The incidence rates of mortality
increased across declining eGFR and higher ACR categories.
The risk of VTE increased with declining eGFRCr-CysC (Table 2.4.); the
unadjusted HRs (95% CI) for eGFRCr-CysC 60-<90, 45-<60 and <45 compared to ≥90
ml/min/1.73m2 were 1.91 (1.45, 2.51), 2.24 (1.41, 3.57) and 3.38 (2.04, 5.60), p trend
<0.001. The HRs were attenuated when adjusting for age, sex, race x region and BMI and
remained statistically significant only for eGFRCr-CysC <45 compared to ≥90
ml/min/1.73m2, HR 2.13 (1.19, 3.76). Associations of eGFRCr-CysC, with provoked and
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unprovoked VTE were similar with a two-fold increased risk for each type of VTE with
eGFRCr-CysC<45 versus ≥90ml/min/1.73m2(Table 2.4.).
In the competing risk analysis, the adjusted cause-specific HRs for mortality
increased with lower eGFRCr-CysC and were higher than the HRs for VTE in each category
of eGFR (Table 2.4.).
ACR was not associated with VTE in univariate or multivariable analysis. As
compared to ACR<10 mg/g, the unadjusted HRs (95% CI) for VTE for ACR 10-<30, 30<300 and >300mg/g were 1.30 (0.96, 1.76), 1.54 (1.06, 2.22), and 1.18 (0.52, 2.66).
Multivariable HRs are shown in Table 2.4.. The HRs were similar for provoked and
unprovoked VTE (Table 2.4.), and for use of the estimated albumin excretion rate (Table
2.6., Supplemental Table S2.1.). The adjusted cause-specific HRs for mortality increased
across higher levels of albuminuria (Table 2.4.).
Race-specific HRs for VTE by kidney disease measures were stratified by
region given the known race x region interaction in REGARDS (Table 2.5.). For whites
residing outside of the southeast, VTE risk increased across categories of eGFRCr-CysC
with a HR (95% CI) 3.37 (1.34, 8.45) for eGFRCr-CysC <45 ml/min/1.73m2. For blacks
residing outside of the southeast, eGFRCr-CysC was not associated with VTE, however the
interaction p value for race*GFR was 0.70 outside the southeast. In the southeast,
associations appeared larger in blacks than whites (p interaction = 0.1), with similar
associations in blacks and whites for eGFR <45 (HR 1.68 and 1.95, respectively) but
higher HRs among blacks than whites for eGFR 45-<90 ml/min/1.73m2. There were no
significant differences in the association of ACR with VTE when stratified by race and
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region (p interaction was 0.9 in southeast, p interaction was 0.3 in non-southeast) (Table
2.7., Supplemental Table S2.2.). There was also no significant interaction between ACR
and eGFR (p interaction = 0.4).
The population attributable fractions of obesity (defined as BMI ≥30 kg/m2) and
older age (defined as age ≥65 years), for VTE were 17% and 36%, respectively. The
population attributable fractions of CKD for VTE by eGFRCr-CysC <90, <60 and eGFRCrCysC

<45 ml/min/1.73m2 were 20%, 5% and 4%, respectively.
In a secondary analysis, the eGFR using alternate equations had similar

associations with VTE (Table 2.8., Supplemental Table S2.3.). The adjusted HR (95%
CI) for eGFR <45 compared to ≥90ml/min/1.73m2 was 1.93 (1.13, 3.32) for eGFRCr, and
1.58 (0.81, 3.08) for eGFRCysC. The HR of VTE with eGFRCr <45ml/min/1.73m2 using
the MDRD equation was 1.94 (1.07, 3.50).

2.5. Discussion
Estimated glomerular filtration rate was independently associated with an
increased risk of future VTE in this large prospective cohort study. Compared to eGFRCrCysC ≥90,

an eGFRCr-CysC <45 ml/min/1.73m2 was associated with a 2-fold increased risk

of VTE, after adjusting for demographic and VTE risk factors. This relationship was
similar for provoked VTE, but the association was not statistically significant in
unprovoked VTE. The association of VTE and eGFR appeared to vary by race and
region, but power limited the interpretation of these analyses. There was no association
between ACR and incident VTE. The cause-specific hazard ratios for mortality were
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higher for each eGFR or ACR category than the risk for VTE. The population attributable
fraction of VTE for CKD was modest compared to that for accepted clinical cut points
for BMI and older age.
Our results provide further evidence supporting the relationship between eGFR
and VTE.7,9,11,21,22 A meta-analysis of five studies, the largest work thus far, demonstrated
an association between eGFR and VTE risk11 and our findings extend this finding to a
large, contemporary U.S. cohort. We hypothesized that different eGFR equations used in
previous research, including individual studies from the meta-analysis, may have led to
conflicting results on the association of kidney disease measures and VTE. In the ARIC
and PREVEND studies, eGFRCr by the MDRD equation was not associated with future
VTE,7,9 however, in ARIC eGFRCysC was associated with VTE. We were able to clarify
the relationship between kidney disease measures and VTE by simultaneously comparing
the relationships of the CKD-EPI (eGFRCr, eGFRCysC, eGFRCr-CysC) and MDRD eGFR
equations, and ACR, with VTE risk in one study. eGFRCr, eGFRCr-CysC and MDRD
eGFRCr were all significantly associated with VTE risk, in sum, supporting a link
between kidney disease measures and VTE. With regards to type of VTE, the association
of eGFR <45 ml/min/1.73m2 was somewhat stronger for provoked VTE than
unprovoked. Uniformly, the risk of VTE begins at an eGFR below 45 ml/min/1.73m2,
suggesting the mechanism of the association between eGFR and VTE could relate to
changes that occur at this level of clearance.
In contrast to eGFR, ACR was not associated with VTE in this study. This is
consistent with the finding in ARIC, the only other epidemiologic study of the
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relationship of ACR and VTE risk performed in the U.S.9 In the Prevention of Renal and
Vascular End-Stage Disease (PREVEND) study, a Dutch cohort that oversampled for
albuminuria, urinary albumin excretion was associated with increased risk of future VTE.
Differences in the cohort composition compared to the REGARDS and ARIC studies
could account for the different results. In PREVEND there were more smokers (38% vs
14%), fewer diabetics (4% vs 20%) and lower BMI (mean BMI 26.1 vs 29.2 kg/m2)
compared to the REGARDS, and people with insulin treated diabetes were excluded.
Race and regional differences in the risk of VTE have been previously reported
in the REGARDS study.16 Therefore, we studied whether race modified the association of
eGFR and VTE within region (southeast/non-southeast). The association of eGFR and
VTE appeared largest in whites residing outside of the southeast. While this may have
been a chance finding and power to detect two-way interactions was limited, the reason
for this finding may be due to the competing risk for death. For eGFR< 45
ml/min/1.73m2, whites outside the southeast had the lowest cause-specific hazard ratio
for death, compared to whites in the southeast or blacks in either region. In the
aforementioned meta-analysis, there was no difference in the association of kidney
disease and VTE by race. Conflicting results may be related to different definitions of
kidney disease and limited number of black participants residing outside of the southeast
included in the meta-analysis.
There are several strengths of the current study. The large, prospective,
population based nature of the study enables our results to be generalized to black and
white Americans living across a geographically diverse region of the U.S. We were able
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to compare associations of kidney disease measures with VTE using several different
equations in one study. The study was a contemporary cohort reflecting current trends in
obesity and medication use (including widespread use of statins) that might alter
relationships of CKD with VTE, and reflects current diagnosis patterns for VTE, which
have changed over the past few decades.23 The presentation of competing risk of death is
unique in the study of kidney disease measures and VTE, and informed our
understanding of potential race and regional differences in the risk of VTE.
Limitations of this study require consideration. As with many other prospective
cohort studies of general populations, GFR was estimated and not measured. The
estimates of GFR and ACR were obtained once at baseline. This could have led to
misclassification. The PREVEND study reported that ACR was less accurate and more
biased than estimated albumin excretion rate,24 because urinary creatinine is influenced
by muscle mass, introducing confounding based on non-albuminuric covariates.25
However, in a sensitivity analysis our results were consistent when utilizing estimated
albumin excretion rate as a predictor. Our analysis may have been limited by low power
to detect smaller differences in risk of VTE by ACR category. With 239 VTE events and
a prevalence of 14% ACR>30 mg/g we estimated 80% power to detect a HR of 1.7 or
higher using alpha<0.05. Despite a large cohort of blacks and whites, power was limited
in studying both race and region stratified associations of kidney disease measures and
VTE. The results may not be generalizable to the entire U.S. population as REGARDS
was limited to self-identified black and white participants above age 45. Finally, while
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we adjusted for factors known to be associated with VTE risk the results could be
influenced by unmeasured factors and residual confounding could exist.

2.6. Conclusions
The present prospective study provides further clarification on a growing
literature supporting a relationship between kidney function and VTE. In our study,
eGFR < 45 ml/min/1.73m2 was associated with a two-fold risk of VTE and a three-fold
risk of mortality. Further study of the mechanisms of the association between low eGFR
and VTE and potential modifiable risk factors is warranted.
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Table 2.1.: Baseline characteristics by categories of eGFRCr-CysC
Characteristic
(mean, SD or frequency, %)

eGFRCr-CysC (ml/min/1.73m2)

N

≥90
14,087

60-<90
8,670

45-<60
1,475

<45
870

Mean age, years
Sex, female
Race, black
Region of Residence, southeast

61.0±8.1
64.4
35.5
57.3

68.5±8.6
40.9
44.6
53.4

72.5±8.8
38.2
48.1
52.3

72.1±9.1
38.5
54.7
51.7

Hypertension
Diabetes
Hyperlipidemia
CVD

48.9
16.1
42.1
11.1

67.0
22.0
46.7
22.5

80.1
34.7
51.7
37.5

87.3
47.5
54.4
44.0

BMI, kg/m2
Smoking
Current
Former
Never

28.9±6.1

29.4±6.0

29.7±6.2

30.1±7.0

14.9
47.9
37.1

13.6
42.0
44.4

12.8
41.2
46.0

12.1
42.2
45.7

Statin use
Aspirin use
Hormone Therapy use*
Warfarin use

27.0
37.8
19.2
1.4

34.5
48.7
11.3
3.7

43.6
53.7
11.1
7.1

47.0
57.2
6.9
7.7

1.0±0.2
1.1±0.1
78±13
72±13
45±316

1.3±0.2
1.4±0.2
56±10
49±9
123±447

0.9±0.8
2.1±0.7
37±12
31±9
440±987

Serum creatinine (mg/dL)
0.7±0.1
Serum cystatin C (mg/L)
0.8±0.1
eGFRcr (ml/min/1.73m2)
96±13
eGFRcysC (ml/min/1.73m2)
102±14
Urine ACR (mg/g)
20±108
*Hormone therapy use for women only.
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Table 2.2.: Baseline characteristics by categories of albumin-to-creatinine ratio (ACR)
Characteristic
(mean, SD or frequency, %)

ACR (mg/g)

N

<10
15,777

10-<30
5,696

30-<300
2,961

≥300
668

Mean age, years
Sex, Female
Race, Black
Region of Residence, Southeast

63.4±9.0
52.9
37.7
55.5

66.5±9.5
59.3
39.5
56.5

67.3±9.9
50.4
48.1
54.3

66.6±9.3
42.4
63.5
53.3

Hypertension
Diabetes
Hyperlipidemia
CVD

51.44
13.8
42.6
14.1

65.5
25.0
46.4
20.9

75.2
37.4
48.7
26.3

87.4
60.45
59.0
37.7

BMI, kg/m2
Smoking
Current
Former
Never

28.9±5.8

29.2±6.4

30.2±6.6

30.7±7.0

13.2
46.6
40.2

14.7
44.8
40.5

17.6
41.8
40.6

20.7
33.5
44.7

Statin use
Aspirin use
HRT use*
Warfarin use

29.0
41.3
19.4
2.0

33.3
45.4
12.2
3.4

36.3
46.8
11.7
4.7

44.5
52.9
8.0
4.6

Serum creatinine (mg/dL)
0.9±0.2
0.9±0.3
1.0±0.4
1.5±1.0
Serum cystatin C (mg/L)
0.9±0.2
1.0±0.3
1.1±0.4
1.6±0.9
eGFRcr (ml/min/1.73m2)
87±17
85±20
81±24
62±29
eGFRcysC (ml/min/1.73m2)
90±22
84±24
76±27
55±28
Urine ACR (mg/g)
5±2
16±5
84±60
1224±1422
Differences were significant (p <0.05) across categories of ACR for all variables except region of
residence. *Hormone therapy use for women only.
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Table 2.3.: Adjusted Incidence Rate (IR) for VTE and mortality per 1000 Person-Years by kidney disease measures
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eGFRCr-CysC
≥90
60-<90
45-<60
<45
p trend
(ml/min/1.73m2)
No. at risk
14,087
8,670
1,475
870
Person-time
66,171
41,580
6,788
3,720
No. VTE
90
110
21
18
VTE IR (95% CI)
1.50 (1.21, 1.85)
2.14 (1.72, 2.66)
2.18 (1.38, 3.46)
3.43(2.09, 5.63)
0.02
No. deaths
666
1,132
428
378
Mortality IR (95% CI)
11.4 (10.6, 12.3)
18.5 (17.2, 19.8)
33.5 (30.0, 37.4)
53.4 (47.4, 60.1)
<0.001
<10
ACR (mg/g)
10-<30
30-<300
≥300
No. at risk
15,777
5,696
2,961
668*
Person-time
75,273
26,732
13,347
2907
No. VTE
135
62
36
6
VTE IR (95% CI)
1.69 (1.42, 2.02)
1.97(1.52, 2.56)
2.16 (1.54, 3.04)
1.70(0.76, 3.81)
0.5
No. deaths
1,020
738
601
245
Mortality IR (95% CI)
11.4 (10.7, 12.2)
19.1 (17.6, 20.6)
28.0 (25.6, 30.7)
54.6 (47.8, 62.2)
<0.001
eGFR is expressed in ml/min/1.73m2 and ACR in mg/g. *Of the 50 participants with ACR>3000mg/g only one VTE in this
category. Incidence rates are adjusted for age, sex and race.

Table 2.4.: Cause specific hazard ratios (95% CI) for total VTE, provoked and unprovoked VTE and mortality by kidney disease measures
eGFRCr-CysC
Crude VTE HR
Adjusted VTE HR
Total

≥90
1.0 (ref)

60-<90
1.91 (1.45, 2.51)

45-<60
2.24 (1.41, 3.57)

<45
3.38 (2.04, 5.60)

1.0 (ref)

1.28 (0.94, 1.76)

1.30 (0.77, 2.18)

2.13 (1.21, 3.76)

Provoked
Unprovoked
Crude mortality HR
Adjusted mortality HR

1.0 (ref)
1.0 (ref)
1.0 (ref)
1.0 (ref)

1.13 (0.73, 1.75)
1.47 (0.93, 2.32)
2.53 (2.29, 2.78)
1.40 (1.26, 1.57)

1.39 (0.69, 2.79)
1.20 (0.55, 2.64)
6.09 (5.39, 6.89)
2.28 (1.97, 2.64)

2.31 (1.07, 4.96)
1.98 (0.86, 4.61)
10.04 (8.84, 11.41)
3.18 (2.72, 3.71)

ACR
Crude VTE HR
Adjusted VTE HR
Total

<10
1.0 (ref)

10-<30
1.30 (0.96, 1.76)

30-<300
1.54 (1.06, 2.22)

≥300
1.18 (0.52, 2.66)

1.0 (ref)

1.14 (0.84, 1.55)

1.15 (0.79, 1.68)

0.65 (0.26, 1.64)

p trend
<0.001
0.01
0.03
0.2
<0.001
<0.001
p trend
0.6
0.4
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Provoked
1.0 (ref)
1.38 (0.91, 2.09)
1.42 (0.85, 2.36)
0.53 (0.13, 2.25)
0.4
Unprovoked
1.0 (ref)
1.92 (0.58, 1.45)
0.92 (0.52, 1.64)
0.78 (0.24, 2.59)
0.7
Crude mortality HR
1.0 (ref)
2.07 (1.88, 2.28)
3.41 (3.08, 3.78)
6.42 (5.58, 7.40)
<0.001
Adjusted mortality HR
1.0 (ref)
1.46 (1.32, 1.62)
1.94 (1.74, 2.20)
2.60 (2.20, 3.06)
<0.001
eGFR is expressed in ml/min/1.73m2 and ACR in mg/g. VTE Cox models are adjusted for age, sex, race x region, BMI. Cox models for mortality are
additionally adjusted for hypertension, diabetes, hyperlipidemia, cardiovascular disease and smoking. Adjusted ACR models are adjusted for eGFR and
vice versa.

Table 2.5.: Adjusted Cause-Specific Hazard Ratios and 95% Confidence Intervals for VTE and mortality by eGFR Cr-CysC stratified by race and
region

VTE

Mortality

eGFR
White
Black

90
1.0
1.0

60-<90
1.21 (0.72, 2.03)
2.18 (1.06, 4.46)

45-<60
0.30 (0.07, 1.31)
3.45 (1.28, 9.31)

Non-southeast

White
Black

1.0
1.0

1.09 (0.61, 1.97)
0.89 (0.39, 2.02)

1.64 (0.64, 4.11)
1.05 (0.33, 3.33)

Southeast

White
Black

1.0
1.0

1.44 (1.20, 1.72)
1.24 (0.95, 1.60)

2.25 (1.76, 2.88)
1.99 (1.41, 2.81)

Non-southeast

White
Black

1.0
1.0

1.33 (1.06, 1.66)
1.46 (1.14, 1.88)

2.12 (1.59, 2.84)
2.37 (1.73, 3.25)

Southeast

<45
p trend
1.95 (0.76, 4.99)
0.7
1.68 (0.36, 7.82)
0.4
p interaction race x eGFR= 0.1
3.37 (1.34, 8.45)
0.007
1.04 (0.26, 4.10)
0.9
p interaction race x eGFR= 0.7
3.03 (2.31, 3.98)
<0.001
3.15 (2.20, 4.50)
<0.001
p interaction race x eGFR <0.001
2.29 (1.64, 3.19)
<0.001
3.36 (2.40, 4.69)
<0.001
p interaction race x eGFR <0.001
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eGFRCr-CysC in ml/min/1.73m2. VTE Hazard ratios are adjusted for age, sex and BMI. Mortality HR are additionally adjusted for hypertension, diabetes,
hyperlipidemia, cardiovascular disease, smoking and albuminuria.

Table 2.6.: (Supplemental Table S2.1.): Age, sex and race adjusted Incidence rate per 1000 Person-Years and Hazard Ratio (95% CI) of VTE for
categories of estimated albumin excretion rate (eAER)
15-<30
30-<300
≥300
P trend
2,548
12,875
8,831
11,897
61,579
40,967
16
128
89
1.25
1.88
1.90
(0.76, 2.04)
(1.57, 2.26)
(1.52, 2.39)
Crude HR
0.84
1.27
1.35
0.3
(0.33, 2.13)
(0.56, 2.89)
(0.59, 3.09)
Adjusted HR
1.0
0.84
1.35
1.22
0.4
(0.33, 2.18)
(0.59, 3.09)
(0.51, 2.91)
eAER is estimated albumin excretion rate in mg/24hr. eGFR in ml/min/1.73m2. Adjusted model is adjusted for age, sex, race, region and race*region and
BMI and eGFRCr-CysC.
eAER
No. at risk
Person-time
No. VTE
Incidence rate (95% CI)

<15
848
3,816
6
1.54
(0.69, 3.44)
1.0
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Table 2.7 (Supplemental Table S2.2.): Adjusted Cause-Specific HRs (95% CI) for VTE and mortality by ACR stratified by race and region
P trend
 300
0.54
0.6
(0.74, 3.93)
Black
1.0
1.27
0.7
(0.30, 5.39)
P interaction race x ACR= 0.9
Non-southeast
White
1.0
1.60
1.15
0.99
0.9
(0.94, 2.71)
(0.53, 2.49)
(0.14, 7.24)
Black
1.0
0.64
1.43
0.55
0.9
(0.26, 1.61)
(0.65, 3.15)
(0.07, 4.11)
P interaction race x ACR= 0.3
Mortality
Southeast
White
1.0
1.51
2.02
2.30
<0.001
(1.28, 1.79)
(1.67, 2.44)
(1.67, 3.16)
Black
1.0
1.32
1.82
2.53
<0.001
(1.03, 1.69)
(1.40, 2.37)
(1.76, 3.64)
P interaction race x ACR <0.001
Non-southeast
White
1.0
1.37
1.84
2.47
<0.001
(1.11, 1.67)
(1.46, 2.33)
(1.66, 3.66)
Black
1.0
1.47
1.99
2.98
<0.001
(1.16, 1.85)
(1.57, 2.54)
(2.20, 4.02)
P interaction race x ACR <0.001
ACR in mg/g. VTE Hazard ratios are adjusted for age, sex, BMI and eGFRCr-CysC. Mortality HR are additionally adjusted for hypertension, diabetes, history
of cardiovascular disease, smoking.
VTE

Southeast

ACR
White

<10
1.0

10-<30
1.04
(0.62, 1.75)
1.19
(0.60, 2.39)

30-<300
1.09
(0.56, 2.12)
1.35
(0.60, 3.01)
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Table 2.8.: (Supplemental Table S2.3.): Incidence Rates Per 1000 PY and Hazard Ratio (95% CI) of VTE for eGFR equations
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CKD-EPI eGFRCr
≥90
60-<90
45-<60
<45
P trend
No. events/N at risk
93/11,433
114/11,013
22/1,799
20/857
Person-time
53,464
52,855
8,244
3,696
Incidence Rate
1.91 (1.56, 2.36)
1.69 (1.37, 2.08)
1.77 (1.13, 2.76)
3.43 (2.15, 5.48)
0.02
(95% CI)
Crude HR for VTE
1.0 (ref)
1.23 (0.93, 1.63)
1.62 (1.02, 2.59)
3.35 (2.06, 5.45)
<0.001
Adjusted HR for
1.0 (ref)
0.86 (0.63, 1.17)
0.92 (0.56, 1.53)
1.93 (1.13, 3.32)
0.02
Total VTE
Provoked VTE
1.0 (ref)
0.76 (0.50, 1.17)
0.76 (0.36, 1.57)
1.96 (0.95, 4.06)
0.09
Unprovoked VTE
1.0 (ref)
1.00 (0.63, 1.57)
1.15 (0.57, 2.32)
1.94 (0.87, 4.31)
0.1
CKD-EPI eGFRCysC
No. events/N at risk
84/11,971
103/9,401
35/2,316
27/1,414
Person-time
56,159
45,322
10,740
6,039
Incidence Rate
1.61 (1.30, 2.00)
1.90 (1.54, 2.34)
2.32 (1.61, 3.33)
2.98 (1.97, 4.49)
0.01
(95% CI)
Crude HR for VTE
1.0 (ref)
1.45 (1.09, 1.95)
2.07 (1.38, 3.10)
3.01 (1.93, 4.68)
<0.001
Adjusted HR for
1.0 (ref)
1.02 (0.74, 1.39)
1.10 (0.70, 1.74)
1.58 (0.95, 2.62)
0.08
Total VTE
Provoked VTE
1.0 (ref)
0.78 (0.50, 1.20)
0.93 (0.50, 1.74)
1.58 (0.81, 3.08)
0.2
Unprovoked VTE
1.0 (ref)
1.36 (0.85, 2.18)
1.36 (0.70, 2.63)
1.62 (0.75, 3.47)
0.2
MDRD eGFRCr
No. events/N at risk
78/9,494
118/12,896
24/1,883
14/636
Person-time
44,045
62,040
8,587
2,809
Incidence Rate (95% CI)
1.79 (1.42, 2.24)
1.69 (1.39, 2.05)
2.06 (1.35, 3.14)
3.54 (2.06, 6.09)
0.42
Crude HR for VTE
1.0 (ref)
1.05 (0.79, 1.40)
1.58 (1.00, 2.50)
2.84 (1.61, 5.02)
<0.001
Adjusted HR for
1.0 (ref)
0.95 (0.70, 1.27)
1.07 (0.66, 1.73)
1.94 (1.07, 3.50)
0.03
Total VTE
Provoked VTE
1.0 (ref)
0.88 (0.59, 1.32)
0.94 (0.47, 1.88)
1.81 (0.79, 4.16)
0.2
Unprovoked VTE
1.0 (ref)
1.03 (0.66, 1.59)
1.22 (0.62, 2.45)
2.12 (0.92, 4.92)
0.06
eGFR in ml/min/1.73m2. Incidence rates are adjusted for age, sex and race. Adjusted Cox models are adjusted for age, sex, race, region and race*region,
BMI and ACR

Figure 2.1.: Flow diagram of participants included in the study. Mutually exclusive
counts in parentheses.
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3.1. Abstract
Background: Chronic kidney disease (CKD) is associated with venous
thromboembolism (VTE) risk via unknown mechanisms. Whether strategies protective
against VTE in the general population might work in CKD is unknown.
Objectives: To determine whether biomarkers of thrombosis risk attenuate VTE risk and
if factors protective against VTE were similarly effective in people with CKD.
Methods: With 4.3 years of follow up, baseline biomarkers were measured in 294
incident VTE cases and 939 non-cases from the REGARDS cohort, a nationwide cohort
of 30,239 persons age 45 and older. The hazard ratio (HR) of VTE per 10 ml/min/1.73m2
lower eGFR, and the percent attenuation of this HR by each biomarker were calculated.
Associations of protective factors, physical activity, lower BMI, aspirin, warfarin and
statin use, with VTE were estimated in those with and without CKD.
Results: The adjusted HR (95% CI) for VTE with lower eGFR was 1.13 (1.02, 1.25), and
this was attenuated 23% (5, 100%) by D-dimer, 100% (50, 100%) by FVIII and 15% (2,
84%) by CRP. Normal BMI was associated with lower VTE risk in those without CKD
(HR 0.47 (0.32, 0.70)) but not with CKD (HR 1.07 (0.51, 2.22) p interaction 0.07). Statin
use, physical activity and warfarin use were associated with lower VTE risk in both
groups.
Conclusions: Procoagulant and inflammatory biomarkers mediated the association of
eGFR with VTE. Higher physical activity, statin and warfarin use mitigated risk of VTE
in those with and without CKD, but normal BMI did not mitigate risk in CKD.
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3.2. Introduction
Kidney disease has recently emerged as a risk factor for venous
thromboembolism (VTE),[1-4] however little is known about mechanisms or clinical
implications of this relationship. Low estimated glomerular filtration rate (eGFR) is
associated with increased levels of biomarkers of inflammation and procoagulation,
including higher levels of C-reactive protein (CRP), D-dimer and factor VIII (FVIII).[57]. Since these alterations are also associated with increased VTE risk,[8-19] they might
account for the relationship of kidney disease with VTE. That is, CKD induced
inflammation and procoagulation may explain part of the relationship between eGFR and
VTE and thus could be considered as mediators. If this is the case, then interventions that
have an impact on the biology represented by these biomarkers could lower VTE risk
associated with CKD.
Epidemiology studies and clinical trials suggest a normal BMI, higher physical
activity,[20-22] statins,[23-25] aspirin and anticoagulants[26-28] reduce the risk of VTE.
However, it is not known if these factors that are protective in the general population are
similarly protective in patients with CKD. Knowledge of whether a particular factor is
equally, or more, effective in CKD could also shed light on potential mechanisms of VTE
in CKD.
In this analysis, we evaluated whether higher levels of D-dimer, Factor VIII
(FVIII) and C-reactive protein (CRP), would attenuate the association of eGFR and VTE.
We also evaluated whether established risk factors and protective medication use exert
similar associations with VTE risk in individuals with versus without CKD.
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3.3. Methods
Study population and design:
We studied participants in the Reasons for Geographic and Racial Differences in
Stroke (REGARDS) cohort, a prospective cohort study of self-reported blacks and whites
in the United States, which has been previously described.[29] In brief, REGARDS
enrolled 30,239 black and white women and men age 45 and older between 2003-2007.
Exclusion criteria included medical conditions preventing long-term participation, active
cancer or active treatment for cancer, residence in or awaiting placement in a nursing
home, or inability to communicate in English. For this analysis, we excluded participants
missing baseline measures of kidney function (serum creatinine and cystatin C), those
with prior self-reported VTE or receiving dialysis at baseline.
Participants were identified from a commercially available list of U.S. residents
and recruited through a mailing followed by telephone contact. The cooperation rate was
49% of eligible participants. After completing a computer assisted telephone interview,
participants underwent an in-home visit, where informed consent was obtained,
anthropomorphic data, medication inventory and urine samples were collected and
fasting phlebotomy and an electrocardiogram were performed. Two blood pressure
measurements were averaged for analysis, and blood samples were collected after a 10 to
12 hour fast. Blood was centrifuged locally and shipped on ice packs to the University of
Vermont for reprocessing and analysis or storage.[30] The study was approved by all
institutional review boards at participating universities.
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Event ascertainment and definitions:
The primary outcome was incident VTE, consisting of deep vein thrombosis
(DVT), pulmonary embolism (PE) or both occurring together. Events were ascertained
and validated as previously described.[31] In brief, VTE events were identified by four
methods: review of reasons for hospitalization from telephone calls every 6 months up to
February 2010; a telephone interview administered from February 2010-February 2011 to
identify any self-report of VTE from baseline to time of the call; review of all deaths
using periodic searches of the National Death Index, exit interviews or records of last
hospital stay; review of medical records for other events such as stroke. For potential
cases, in-patient and outpatient medical records were retrieved and then reviewed and
adjudicated by two physicians. Major disagreements were settled by a blinded third
physician.
Estimated glomerular filtration rate (eGFR) was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation[32] based on
creatinine and cystatin C.[33] Baseline covariates of interest included age, sex, race (selfreported black or white), region of residence (southeast or non-southeast), body mass
index (BMI) in kg/m2, diabetes, hyperlipidemia, cardiovascular disease (CVD), physical
activity frequency (self-report of 0, 1-3 or 4 or more times per week), self-report of
regular aspirin use, and statin or warfarin use determined by pill bottle review. Southeast
was defined as residing in Alabama, Arkansas, Georgia, Louisiana, Mississippi, North
Carolina, South Carolina or Tennessee. Diabetes was defined as fasting glucose 126
mg/dL, random glucose 200 mg/dL, or taking insulin or glucose lowering medications.
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Hyperlipidemia was defined as cholesterol >240 mg/dL, low density lipoprotein >160
mg/dL or taking medications for high cholesterol. CVD was defined as self-report of prebaseline myocardial infarction, coronary artery surgery, angioplasty, stenting, silent MI
on electrocardiogram or stroke. CKD was defined as eGFR less than 60 ml/min/1.73m2
by convention In REGARDS, albuminuria was not associated with VTE[1] so this was
not considered. Normal BMI was defined as 18.5- <25 kg/m2.

Case-Cohort Study Design:
We used previously measured biomarker data for D-dimer and FVIII from a
cohort random sample (CRS), selected as previously described.[34] The CRS was
randomly selected within strata of race, sex and age to ensure sufficient representation of
high-risk groups. To these data, we added measurement of these biomarkers in 294 VTE
cases. For analyses conducted in this case-cohort sample we excluded participants
missing lab data (Table 3.6., Supplemental Table S3.2.).

Laboratory:
In the full cohort, serum creatinine was measured using an isotope-dilution mass
spectrometry-traceable method using the Vitros 950IRC instrument (Johnson & Johnson
Clinical Diagnostics, Rochester, NY), with a coefficient of variation (CV) of 1.1%.
Serum cystatin C was measured with high sensitivity particle-enhanced
immunonephelometry (N Latex Cystatin C on the BNII, Dade Behring, Deerfield, IL),
with an intra-assay CV of 2.0-2.8% and an inter-assay CV of 2.3-3.1%. CRP was
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measured by particle enhanced immunonephelometry using the BNII nephelometer (N
High Sensitivity CRP, Dade Behring, Deerfield, IL) with inter-assay CV of 2.1–
5.7%.[35]
For this VTE case-cohort study, D-dimer and FVIII were measured in 2015 in
VTE cases and harmonized with measurements made previously in the CRS in 2012. The
CRS D-dimer was run in plasma using an immunoturbidometric assay on the STA-R
analyzer (Diagnostica Stago, Asnières sur Seine, France; inter-assay CV 3.2-27.1%) and
VTE cases were run on the STA-R Evolution analyzer (Diagnostica Stago, Asnières sur
Seine, France; inter-assay CV 1.5-21.7%). FVIII was measured using an ELISA with a
CV of 4-7% (Enzyme Research Laboratories, South Bend, IN), with units of % of
normal.
Given that analytes in cases and the cohort sample were measured at two
different times, and for D-dimer with two different analyzers, we evaluated for analytical
drift in assay results using three approaches (Table 3.7., Supplemental Table S3.2.). We
detected a laboratory shift in D-dimer values after the introduction of a new analyzer in
2014, which was verified in a set of experiments. There was no analytic drift observed for
FVIII, however, the correlation between analytes in 2012 and 2015 was weaker, which
we attributed to higher analytical CVs. To harmonize results, we adjusted the D-dimer
values for VTE cases down by 0.05 µg/mL.
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Statistical analysis:
In this report, we examine both the potential of mediation for selected biomarker
and effect modification by CKD status.
For the mediation analysis, we compared baseline characteristics among
participants with VTE and those in the cohort sample using chi-squared tests and t-tests
as appropriate. D-dimer and CRP were highly skewed and thus natural log transformation
was used for the analyses. We present back-transformed (geometric) means (95% CI) of
log transformed variables in the results. We used linear regression to study the crosssectional association of eGFR and biomarker levels (D-dimer, FVIII and CRP). We
adjusted for demographics (age, sex, race and region of residence), and covariates that are
known to be related to these biomarkers: BMI, hypertension, hyperlipidemia, diabetes,
history of cardiovascular disease and smoking. Cox proportional hazards models were
used to determine the hazard ratio (HR) for VTE per SD increment of each biomarker.
Those without an event or who died of non-VTE related causes were censored at that
time or at the time of last follow-up, whichever occurred first. We accounted for
population weighting of the CRS using the Barlow method.[36] A base model adjusted
for age, sex, race, region and BMI. We calculated the adjusted HR of VTE per 10-unit
lower eGFR, then added each biomarker separately to the base model. To estimate the
magnitude of the potential mediation of the association of CKD with VTE by each
biomarker we calculated the percent attenuation of the HR: Percent attenuation = 100% x
(HR without biomarker – HR with biomarker) /(HR without biomarker – 1). The 95% CI
of the percent attenuation of the HR for eGFR and VTE was calculated using
82

bootstrapping with replacement with 1000 replicate samples. If the percent mediation was
greater than 100% we reset that value to 100%. To verify that our results from the casecohort study were representative of the full REGARDS study, we performed a sensitivity
analysis by repeating the same analysis with CRP, which was measured in the entire
cohort, and presented these results for qualitative comparison.
To study effect modification by CKD status, in the full cohort we obtained riskestimates for established VTE risk factors and protect medication use from stratified Cox
models with CKD as the stratification variable. We formally tested for an interaction
between each protective factor and CKD using interaction terms, interpreted as
significant if p interaction <0.10. Models were adjusted for age, sex, race, region and
BMI.
Violations of the proportional hazards assumption were tested visually and with
Schoenfeld tests. For the primary predictor (eGFR), non-proportionality was further
tested with an interaction term, eGFR x time, and HR were estimated at various time
points. For FVIII, Schoenfeld testing demonstrated significant violation of the
proportional hazards assumption but this was not confirmed with observed vs predicted
plots or smoothed estimates of the log HR. All statistical analyses were performed using
Stata software version 14 (StataCorp LP, College Station, TX) and SAS version 9.4 (SAS
Institute Inc., Cary, NC).
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3.4. Results
The case-cohort sample included 1,467 participants, with 386 being VTE
cases. Among these, after excluding those with missing measures of kidney function (n=
88), study biomarkers (n=9), receiving dialysis (n=9), or who reported pre-baseline VTE
(n= 143), there were 1,233 participants in the case-cohort sample (294 VTE cases) (Table
3.6., Supplemental Table S3.1.).
The VTE cases were more likely to be male and white compared to non-cases.
Comorbid conditions were similar between cases and non-cases other than BMI which
was higher in cases. The eGFR was lower in VTE cases than the cohort sample, and
markers of inflammation and procoagulation were higher (Table 3.1.).
Lower eGFR was associated with higher levels of biomarkers of inflammation
and procoagulation. In the cohort sample, adjusting for demographics and cardiovascular
risk factors, each 10 ml/min/1.73m2 lower eGFR was associated with a higher level of
natural log (ln) D-dimer 0.05 µg/mL (95% CI 0.01 0.08), Factor VIII 6.6% (95% CI 4.5,
8.4%) and ln-CRP 0.08 mg/L (95% CI 0.04, 0.15) (Table 3.2.). The adjusted HRs of VTE
were 1.69 (95% CI 1.49, 2.02) per SD higher ln-D-dimer, 2.23 (95% CI 1.98, 2.62) per
SD higher FVIII and 1.29 (1.09, 1.52) per SD higher ln-CRP (Table 3.3.).
Mean follow-up time was 4.3 years. The eGFR was inversely associated
with VTE risk. For each 10 ml/min/1.73m2 lower eGFR, the HR (95% CI) for VTE was
1.13 (1.02-1.25), after adjusting for demographics and VTE risk factors. After adjusting
for ln-D-dimer, Factor VIII and ln-CRP individually, the HRs (95% CI) for VTE were
attenuated 1.10 (0.99, 1.21), 0.98 (0.87, 1.11) and 1.11 (1.00, 1.22) respectively (Table
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3.4.). Including all three biomarkers the HR was 0.99 (0.88-1.11). The percent
attenuation of the HRs (95% CI) were 23% (5,100%) for ln-D-dimer, >100% (50, 100%)
for Factor VIII, 15% (2, 84%) for ln-CRP and >100 % (44, 100%) for all three
biomarkers (Figure 3.1.).
The proportional hazards assumption may have been violated for eGFR and
FVIII. Stratification of FVIII at median FVIII values demonstrated proportional hazards
for VTE. There was a statistically significant interaction between eGFR and time, thus
we modeled the HR for VTE at 1, 3 and 5 years follow up. The association of eGFR and
VTE decreased over time but attenuation by FVIII was similar across follow up time
periods. (Table 3.8., Supplemental Table S3.3.).
In a sensitivity analysis utilizing the full cohort, for each 10 ml/min/1.73m2
decrease in eGFR the age, sex, race and BMI-adjusted HR (95% CI) of VTE was 1.09
(1.02, 1.16). After the addition of ln-CRP the HR (95% CI) was 1.07 (1.00, 1.15), for a
percent attenuation (95% CI) of 22% (5-69%).
The association of mitigating factors for risk of VTE were assessed in the
full cohort, and stratified by CKD status, with results shown in Table 3.5.. Statin use was
associated with a reduced risk of VTE; the HR was 0.68 (95% CI 0.50, 0.93) in the full
cohort with a similar HR in the non-CKD group, and a weaker relationship in the CKD
group, although this difference was not statistically significant (p interaction of statin use
and CKD 0.61). In the full cohort and in those without CKD, normal BMI was associated
with a ~50% lower risk of VTE, but there was no association in those with CKD (p
interaction BMI and CKD = 0.07). We observed inverse associations of warfarin use and
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physical activity with VTE which were similar in those with and without CKD, although
the 95% confidence intervals for these HRs included 1.0. Aspirin use was not associated
with risk of VTE in the full cohort, or in those with or without CKD.

3.5. Discussion
In this prospective study, the association of eGFR with VTE was attenuated
by D-dimer, CRP and in particular Factor VIII. Overall, normal BMI was strongly
protective against VTE, but this relationship was present only for those without CKD,
and was absent in those with CKD. Statin use was associated with reduced risk of VTE
overall, and this association was weaker in those with compared to without CKD,
although this difference was not statistically significant. Warfarin use and physical
activity were similarly associated with reduced risk of VTE in both those with and
without CKD. Baseline aspirin was not associated with lower risk of VTE in either those
with or without CKD.
Our findings suggest that CKD-induced activation of inflammation and
procoagulation are in the causal pathway between eGFR and VTE. We confirmed prior
literature that the studied biomarkers D-dimer[5, 7, 37] FVIII[4, 5, 7] and CRP[38, 39]
are more adverse with worsening kidney function (confirming our rationale to choose
them for this study). We also confirmed that D-dimer,[8] FVIII[10, 18] and CRP[14]
were strongly associated with VTE. We are aware of only one prior study of mediators of
the relationship between eGFR and VTE; The Multiple Environmental and Genetic
Association (MEGA) case-control study included 2,473 patients with recent VTE and
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2,936 matched controls in the Netherlands between 1999-2004 and accounted for genetic
mutations and confounders such as recent surgery or immobilization.[4] Similar to
findings here, adjustment for FVIII or von Willebrand factor (vWF) measured after the
VTE fully explained the association of eGFR and VTE, supporting the conclusion of
both studies that FVIII and/or vWF may mediate the association of kidney function with
VTE. In that study, there was no mediation by anticoagulant factors, including protein C,
protein S or antithrombin. One limitation of the MEGA study is that blood samples were
collected three months after the VTE, thus biomarkers might have been elevated due to
the recent thrombosis, and eGFR might have changed after the VTE as well. VTE may
also have caused greater increases in FVIII and vWF in those with versus without CKD,
possibly explaining the observed mediation. In our study, kidney function and biomarkers
were measured at baseline, prior to the VTE, and participants with previous VTE were
excluded from the analyses. Our findings confirmed the MEGA findings, reducing the
likelihood that the discussed factors were important limitations in that study, and
strengthening a conclusion that FVIII and/or vWF are mediators of this association.
Unlike MEGA, we evaluated inflammation, as measured by CRP, and coagulation
activation, measured by D-dimer, as potential mediators of the association of eGFR and
VTE. The risk of VTE was attenuated by both biomarkers, but to a lesser extent than by
FVIII. An alternative explanation for both studies findings is that these biomarkers are
confounders but not mediators of the association of CKD with VTE. We are not aware of
other studies addressing these two biomarkers.
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Given our finding that FVIII played a larger role in the association of eGFR
and VTE than CRP or D-dimer, further discussion is warranted, specifically on the
potential role of FVIII as mediator in the association of eGFR with VTE. FVIII is a
glycoprotein procofactor that is essential to coagulation. It is produced in liver sinusoidal
cells and endothelial cells and circulates bound to vWF in an inactivated form. When
blood vessel injury occurs, it separates from vWF and acts a cofactor in the conversion of
Factor IX to Factor IXa. When not bound to vWF, FVIII is rapidly catabolized in
circulation via LDL-receptor-related protein (LRP), a hepatic clearance receptor that is
reduced in kidney disease.[40-42] Our model that included all three biomarkers had
similar point estimates to that of the model with just FVIII. One possibility for this is that
inflammation as measured by CRP and procoagulation as measured by D-dimer exert
their effects upstream, by promoting FVIII activity or by impairing FVIII degradation.
Despite the potential joint mechanisms by which inflammation and procoagulation may
be increasing the risk of VTE in CKD, Factor VIII appears to play a larger role. FVIII has
an established role in the etiology other cardiovascular diseases[43, 44] and in
progression of CKD as well[45-47].
As CKD has only recently emerged as a risk factor for VTE, there is little
data on primary prevention of VTE in CKD. Here, we studied the potential for lifestyle
factors and medications to reduce the risk of VTE in those with and without CKD by
determining if there was an interaction between CKD and a protective factor. If we found
a factor was associated with reduced risk of VTE in CKD it might elucidate mechanisms
of VTE in CKD and point to interventions that could be useful to lower the risk. Our
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findings raise hypotheses that warfarin use, statin use and higher physical activity might
mitigate VTE risk in those with CKD, although power limited our interpretations in some
cases leading to confidence intervals that included 1.0. Considering warfarin use, we
excluded those who had prior VTE, so participants presumably had a different indication
for warfarin, e.g. atrial fibrillation or a mechanical heart valve. The wide confidence
intervals (particularly in the CKD group) may be due to low numbers of events,
imprecision of the predictor (i.e. baseline use not reflecting use at time of the VTE),
under-dosing in CKD (due to concern for bleeding, alterations in non-renal clearance), or
difficulties in achieving stable international normalized ratios in CKD. Whether warfarin
would be practical in primary prevention of VTE in those with CKD would require a
randomized controlled trial to determine, and must take into account the bleeding risk,
which might offset any protective effect.[48, 49] Our finding related to statin use
confirms prior work[24, 50] and suggests further study of statins (which do not cause
bleeding) in VTE prevention in CKD patients. Our finding of no association of regular
aspirin use with VTE risk agree with prior research.[51] An association of increased
physical activity with lower VTE risk has been reported previously[20, 21] further study
of its role in VTE prevention seems worthy. In contrast, our findings suggest that
attaining a normal BMI might lower VTE risk in those without CKD, but not in those
with CKD. One hypothesis to explain this is that the inflammatory or pro-coagulant
pathways of CKD outweigh any impact that normal BMI might have in reducing VTE
risk in CKD. Alternatively, lower BMI in CKD may be due to unmeasured confounding
illness, which would mask a protective effect of lower BMI for VTE.
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There are several strengths to this study. This was a prospective study where
kidney function and biomarker levels were measured prior to onset of VTE, and this
might better elucidate mechanistic pathways of CKD-related VTE risk. The study was a
contemporary cohort that reflects current use of statins and trends in obesity and diabetes
relevant to the U.S. population. We had excellent representation of white and black
participants, unlike many studies of VTE epidemiology. In addition, we evaluated the
role of lifestyle factors in risk of VTE stratified by CKD status, to attempt to develop
hypotheses for how CKD patients could reduce their risk of VTE.
There are limitations of this study to consider. The biomarkers were
measured at baseline which may have led to misclassification if biomarker level changed
prior to the VTE. The biomarkers in cases were measured later than the cohort random
sample, and in some cases with different analyzers, but we took several steps to
harmonize the data. Also, we were unable to determine whether low eGFR preceded or
was the result of inflammation and procoagulation. It is possible that inflammation and
procoagulation cause both CKD and VTE through independent pathways. That is,
misclassification of the mediator, unknown confounding between mediator and outcome
and interaction between mediator and exposure are potential limitations. We
demonstrated that the association of eGFR and VTE decreased with time, which may
have led to underestimation of the effect size and the mediation by biomarkers. Due the
blood sample processing methods in REGARDS we were unable to evaluate the role of
platelet function, proteins released by platelets or vWF,[30] all of which may be other
factors linking CKD with VTE. Warfarin is known to reduce the risk of VTE but the
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association was weaker than might be expected in our study. Reasons for this could be
insufficient power to detect this association given only 3% of the cohort reported
warfarin use or failure of baseline use to reliably indicate continuous use up to the time of
VTE. Direct oral anticoagulants could not be evaluated here due to the time when the
study was performed. Finally, although we adjusted for established VTE risk factors,
there may be other factors not considered that would lead to residual confounding.

3.6. Conclusion
In this study, markers of inflammation and procoagulation that are associated
with both lower eGFR and VTE may mediate the association of eGFR and VTE. Normal
BMI was protective against VTE but not in participants with CKD. Higher physical
activity, statin and warfarin use mitigated risk of VTE in those with and without CKD,
offering possible targets for intervention studies. Additional studies are necessary to
confirm whether biomarkers like FVIII might serve as surrogate markers in trials to
reduce the risk of VTE in CKD.
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Table 3.1.: Baseline characteristics of REGARDS case-cohort participants
Characteristic
Age (years)
Female
Black
Southeast

No VTE
N=939
68 ± 12
49
49
52

VTE
N=294
69 ± 8
41
38
53

Hypertension
Diabetes
Hyperlipidemia
Cardiovascular disease
.0

60
20
41
19
28.7 ± 5.8

64
20
41
23
30.2 ± 5.7

Physical activity
- 0 x week
- 1-3 x week
- 4+ x week

35
36
29

41
35
25

Smoking
- Current
- Never
- Past

15%
48%
37%

12%
42%
46%

eGFR ml/min/1.73m2

87 ± 23

80 ± 21

D-dimer (median, IQR) µg/ml
0.5 (0.3-0.9)
0.7 (0.4 - 1.2)
FVIII %
124 ± 45
165 ± 60
CRP (median, IQR) mg/L
2.1 (0.9- 4.9)
2.7 (3.1 - 6.1)
Abbreviations: BMI body mass index. eGFR estimated glomerular filtration rate. FVIII Factor VIII. CRP
C-reactive protein. Continuous variables are presented as mean ± standard deviation (SD) unless noted.
Frequency are presented as percentages unless noted.
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Table 3.2.: Association of eGFR and biomarkers of inflammation and
procoagulation in the cohort sample
Difference in biomarker (95% CI)
per 10 ml/min/1.73m2 lower eGFR

D-dimer (µg/ml)
FVIII (%)
CRP (mg/L)

Unadjusted

Adjusted

0.12 (0.09, 0.15)
5.8 (4.5, 7.1)
0.07 (0.03, 0.11)

0.05 (0.01, 0.08)
6.4 (4.5, 8.4)
0.09 (0.04, 0.15)

Abbrevations: CI, confidence interval; eGFR, estimated glomerular filtration
rate; FVIII, Factor VIII; CRP, C-reactive protein. Linear regression models were
adjusted for age, sex, race, region, BMI, hypertension, diabetes, hyperlipidemia,
cardiovascular disease, smoking. D-dimer and CRP were highly skewed and
were log transformed.
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Table 3.3.: Association of biomarkers and risk of VTE
HR (95% CI) per SD increment of each biomarker
Unadjusted

Adjusted

D-dimer

1.77 (1.51, 2.07)

1.69 (1.41, 2.02)

FVIII

2.14 (1.80, 2.53)

2.23 (1.89, 2.62)

CRP

1.34 (1.16, 1.56)

1.29 (1.09, 1.52)

Abbreviations: HR, hazard ratio; CI, confidence interval; SD, standard deviation;
FVIII, Factor VIII; CRP, C-reactive protein. Cox models were adjusted for age, sex,
race, region, race*region and BMI. D-dimer and CRP were log transformed.

94

Table 3.4.: Association of eGFR and incident VTE with adjustment for biomarkers of procoagulation and inflammation
Model

HR (95% CI) of VTE
per 10-unit lower
eGFR

HR (95% CI) of VTE by quartile of eGFR (ml/min/1.73m2)
Q1
(7-≤71)

Q2
(>71-≤87)

Q3
(>87-≤103)

Q4
(>103-107)

Cases (n)

66

74

60

47

Cohort sample (n)

233

225

239

252

Case-Cohort Study

95

Base Model*

1.13 (1.02, 1.25)

1.39 (0.77, 2.49)

1.19 (0.71, 2.01)

1.06 (0.65, 1.74)

1.0

Base Model + D-dimer

1.10 (0.99, 1.21)

1.12 (0.62, 2.05)

1.11 (0.65, 1.91)

1.06 (0.64, 1.76)

1.0

Base Model + FVIII

0.98 (0.87, 1.11)

0.69 (0.35, 1.37)

0.60 (0.32, 1.11)

0.86 (0.50, 1.48)

1.0

Base Model + CRP

1.11 (1.00, 1.22)

1.24 (0.68, 2.24)

1.15 (0.69, 1.94)

1.03 (0.63, 1.69)

1.0

Base Model

1.09 (1.02, 1.16)

1.46 (0.91, 2.36)

1.13 (0.72, 1.80)

0.97 (0.61, 1.54)

1.0

Base Model + CRP

1.07 (1.00, 1.15)

1.36 (0.84, 2.19)

1.09 (0.69, 1.72)

0.96 (0.60, 1.52)

1.0

Full Cohort

Abbreviations: HR, hazard ratio; CI, confidence interval; Q, quartile; FVIII, Factor VIII; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate.
eGFR as a predictor is presented as a continuous variable (HR per 10 ml/min/1.73m 2 decrement) and as quartiles with reference group as the highest quartile
of eGFR. Cox models were adjusted for age, sex, race, region, race*region and BMI (Base Model*) and biomarkers individually. D-dimer and CRP were log
transformed.

Table 3.5.: The association of lifestyle factors and medications with the risk of VTE, stratified by CKD status
HR (95% CI) of VTE

Regular Aspirin Use

Statin Use

Warfarin Use

N cases
N non-cases

N cases
N non-cases

N cases
N non-cases

P interaction of
Protective Factor x
CKD Status

Overall
(n = 25,936)

CKD
(n = 2,473)

No CKD
(n = 23,463)

124
11,059
1.08 (0.81, 1.43)

22
1,341
0.96 (0.51, 1.79)

102
9,718
1.07 (0.80, 1.41)

0.64

70
8,005
0.68 (0.50, 0.93)

16
1,078
0.86 (0.46, 1.64)

54
6,927
0.67 (0.49, 0.93)

0.61

4
704
0.30 (0.07, 1.21)

2
177
0.70 (0.17, 2.94)

2
527
0.29 (0.07, 1.19)

0.41

96

Physical activity
1-3 x/week vs none

N cases
N non-cases

83
9,214
0.82 (0.59, 1.14)

12
700
0.88 (0.43, 1.81)

71
8,514
0.82 (0.59, 1.14)

Physical activity
4+/week vs none

N cases
N non-cases

66
7,622
0.76 (0.53, 1.07)

8
539
0.73 (0.32, 1.67)

58
7,083
0.76 (0.53, 1.08)

BMI<25 vs 25

N cases
N non-cases

41
6,410
0.48 (0.32, 0.70)

10
545
1.07 (0.51, 2.22)

31
5,865
0.47 (0.32, 0.70)

CKD is defined as eGFR < 60 ml/min/1.73m2. Models were adjusted for age, sex, race, region, race*region, BMI.

0.98

0.07

Table 3.6.: (Supplemental Table S3.1): Exclusion criteria
Exclusion Criteria

Missing follow up
Missing renal function
Missing biomarker
Receiving dialysis
Baseline VTE
Final Cohort

Cohort Random
Sample
N=1,081

VTE
cases
N=386

Case-Cohort
Sample
N=1,467

-72
-6
-3
-61
939

-16
-3
-5
-68
294

-88
-9
-8
-129
1,233
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Full Cohort
N=30,239
-684
-1767
n/a
-113
-1739
25,936

Table 3.7.: (Supplemental Table S3.2): Methodological approaches to studying analytic drift in
REGARDS case-cohort study of VTE risk
Approach
Description

Sample set
Purchased set of donor
samples are run along
with each new set of
analytes (FVIII and Ddimer in 2012 and 2015
with CRS and VTE
cases, respectively)

Duplicates
FVIII and D-dimer were
run in the CRS in 2012.
All VTE cases were run
in 2015. Some
participants of the CRS
developed VTE and had
duplicate analytes in
2015.

LITE study
D-dimer only. Two
analyzers were used
(Sta-R and Evolution).
Repeat measures
performed in 888
samples on both
analyzers in 2014 over
5-day period.

Number of analytes

20

59

700

Results

-D-dimer was 0.10
µg/ml higher in 2015 vs
2012. Mean CV was
39.7% (range 5.473.9%). No difference
comparing freeze thaw
cycles x1 vs x5 in 2015
(r = 0.99; R2= 0.98).

-D-dimer was 0.06
µg/ml higher in 2015
(Evolution) vs 2012
(Sta-R). r = 1.00; R2=
0.97

-D-dimer was 0.05
µg/ml higher in
Evolution vs Sta-R).
r = 0.97; R2= 0.93.

-mean FVIII 26% higher
in 2015. r = 0.84; R2=
0.71

-FVIII levels did not
change over time. Mean
CV 6.7% (5.1121.30%).
Abbreviations: FVIII, Factor VIII; CRS, cohort random sample; vs, versus; r, correlation coefficient; R2,
coefficient of determination; LITE, Longitudinal Investigation of Thromboembolism Etiology study.
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Table 3.8.: (Supplemental Table S3.3): Association of eGFR and VTE at 1, 3, 5 years follow up
HR (95% CI) of VTE per 10 ml/min/1.73m2

Case-Cohort

Full Cohort*

99

Year 1

Year 3

Year 5

N cases, cumulative

26

110

198

Base model

1.23 (1.11, 1.37)

1.13 (1.05, 1.22)

1.04 (0.95, 1.14)

Base + FVIII

1.10 (0.94, 1.29)

1.00 (0.89, 1.13)

0.91 (0.79, 1.06)

N cases, cumulative

25

108

250

Base model

1.18 (1.06, 1.31

1.10 (1.03, 1.18)

1.03 (0.94, 1.12)

Abbreviations: HR, hazard ratio; CI, confidence interval; FVIII, Factor VIII; eGFR, estimated glomerular filtration rate. Base
model includes age, sex, race, region, race*region and BMI. *FVIII was not measured in the full cohort.

Inflammation and
procoagulation

CKD

FVIII 100% (50-100%)
D-Dimer 23% (5-100%)
CRP 22% (5-69%)

VTE

Unexplained factors

Figure 3.1.: Potential mediators of the association of eGFR and Venous
Thromboembolism: Role of biomarkers of inflammation and procoagulation
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